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Lysophosphatidic acid (LPA) is a potent bioactive phospholipid mediator that 
functions through multiple G protein couple receptors (GPCRs). LPA is elevated in ascites 
of ovarian cancer patients and is involved in growth, survival and metastasis of ovarian 
cancer cells. Gene promoter analyses revealed that some LPA-target genes share similar 
sets of binding sites for prominent transcription factors posing the possibility of a general 
mechanism for activation of their expression by LPA. Detailed investigation of the 
  xviii
mechanisms of regulation of cyclooxygenase 2 (Cox-2), a paradigm of LPA-regulated 
genes, showed that LPA robustly upregulated the expression of Cox-2 in ovarian cancer 
cells through multiple receptors. LPA induced rapid increase in Cox-2 mRNA and 
significantly enhanced the stability of Cox-2 transcript with the support of mRNA binding 
protein HuR. The effects of LPA on Cox-2 transcriptional activation include essential 
involvement of transcription factor, C/EBP-β. Further studies on mechanisms of activation 
of C/EBP-β demonstrated that LPA increased phosphorylation, binding and transcriptional 
activities of C/EBP-β. In addition, activation of C/EBP-β and LPA-target genes required 
contribution from EGFR. This novel crosstalk between LPA GPCRs and EGFR in 
mediating transcription factors activation was further explored by investigating the 
mechanisms of activation of AP-1 and NF-κB by LPA. Activation of AP-1 family of 
proteins by LPA relied heavily on basal inputs from EGFR as inhibition of EGFR kinase 
activity with AG1478 caused significant loss of LPA-induced AP-1 expression, binding 
and transcription activities. Although HGF and other agonists of RTK only weakly 
stimulate LPA-target genes and transcription factors in ovarian cancer cells, costimulation 
with HGF in the presence of AG1478 restored LPA signals to both C/EBP-β and AP-1. 
This suggests an obligatory role for a RTK in LPA-induced transcriptional activation, not 
necessarily inputs from EGFR. Interestingly, inhibition of EGFR with AG1478 did not 
interfere with LPA-induced NF-κB activation. Pharmacological inhibition and molecular 
targeting revealed that only a subset of G proteins participate in the crosstalk between LPA 
receptors and EGFR. Collectively, these results demonstrate the presence of at least two 
  xix
signals downstream of LPA receptors: one dependent on basal RTK activity and another 
mediated directly by LPA GPCRs.  
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CHAPTER ONE 
INTRODUCTION 
1.0 OVERVIEW 
Cancer is a disease of uncontrolled cell growth. Cancer cells often possess the 
ability to invade adjacent tissues through the release of substances or molecules that can 
degrade the tissue material. Some of these malignant cells may also spread to distant sites 
in the body via the blood or lymph, a process known as metastasis. All aspects of cancer 
development, survival and progression are strongly anchored on abnormal gene 
expression, a consequence of bypass of critical points of gene regulation. Many cancer 
types originate from cells that possess gene mutations, deletions or amplifications. As 
such, certain cellular functions including activation of transcription factors or 
posttranslational modifications of synthesized proteins become highly enhanced. Tumor-
suppressing genes are inactivated while growth-promoting oncogenes are continually 
turned on, giving the cells new properties, particularly growth advantages. Major 
mechanisms responsible for the enhanced growth of malignant cells include reduce 
dependence on growth factor, insensitivity to growth inhibition, evasion from programmed 
cell death (also called apoptosis), and unlimited growth potentials. The adverse effects of 
cancer on patients are therefore mainly due to tumor burden from increased cell number 
  21
from the dysregulated cell growth. Most cancer therapies target the reduction of cell 
number and the prevention of further accumulation of tumor cells. 
Ovarian cancer remains the leading cause of death from gynecological cancer and 
the fifth leading cause of death from cancer in women. According to the American Cancer 
Society, there are an estimated 21,650 new cases of ovarian cancer and 15,520 deaths due 
to this malignancy in the United States in 2008 [1]. Ovarian epithelial carcinoma is the 
most common type of ovarian cancer. This type includes endometrioid carcinoma, serous 
carcinoma, mucinous carcinomas, clear cell carcinoma and borderline tumor. Ovarian 
cancer is classified into four stages (Stages I-IV). Most tumor markers are insufficient to 
detect ovarian cancer at early Stages I and II because they either lack sensitivity and 
specificity for ovarian cancer or are not elevated until advanced stages of the disease. 
Hence, ovarian cancer has been termed a “silent killer” due to of the lack of symptoms or 
accurate tumor markers at the early stages leading to poor prognosis. 
At the advanced Stages III and IV, ovarian cancer is often characterized by 
extensive intraperitoneal distribution of tumors and formation of large volumes of ascitic 
fluid. The ascitic fluid from ovarian cancer patients contains the ovarian tumor cells and a 
broad range of potent growth factors including lysophosphatidic acid (LPA) [2, 3]. The 
levels of LPA in the plasma of ovarian cancer patients, including those at early stages, are 
significantly higher than those in normal controls [2, 4]. Up to 80 μM LPA has been found 
in the ascitic fluid of ovarian cancer patients [4-6]. LPA is therefore considered to be 
biomarker for ovarian cancer. It is now known that LPA influences many processes of 
tumor cells including growth, survival migration and metastasis [7, 8]. LPA mediates these 
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processes at least partially through regulating the expression of diverse genes and 
metabolic pathways [9-12]. Understanding the detailed mechanisms by which LPA 
regulates gene expression may lead to identification of critical therapeutic targets for the 
treatment of ovarian cancer and perhaps, other cancer types. 
 
1.1 Metabolism of LPA 
LPA (1-acyl-sn-glycerol-3-phosphate) is a naturally-occurring phospholipid. It can 
be produced by different cell types including activated platelets [13, 14], endothelial cells 
[15], fibroblasts [16], adipocytes [17], prostate [18] and ovarian cancer cells [7]. Thus, it is 
present in body fluids including plasma (bound to albumin), saliva, hair follicles and 
malignant effusions [19, 20]. There are multiple pathways potentially responsible for the 
endogenous generation of LPA particularly the actions of certain enzymes on 
phospholipids of the cell membranes [13, 21]. A major part of LPA produced by activated 
platelets is synthesized by the sequential actions of phospholipase A1 or A2 (PLA1/2) on 
serum or membrane phospholipids such as phosphatidylcholine (PC) followed by 
hydrolytic actions of a lysophospholipase D (lysoPLD) present in plasma (Fig. 1.1). 
Recently, autotaxin (ATX), an exo-phosphodiesterase, implicated in cell motility was 
found to be an important enzyme in the production of LPA and the predominant source of 
extracellular LPA [19, 22]. ATX is synthesized as a full-length, or pre-pro-enzyme, that is 
proteolytically cleaved in transit along the classical export pathway and secreted as a 
catalytically active glycoprotein [23]. With its intrinsic lysoPLD activity, ATX can 
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hydrolyze lysophosphatidylcholine (LPC), a major phospholipid secreted by hepatocytes 
and therefore abundant in blood and plasma [24-26], into LPA. The phosphorylation of 
monoacylglycerol by acylglycerol kinase (AGK) is another source of LPA [18]. When 
overexpressed, AGK in the mitochondria is able to mediate the production and secretion of 
LPA by phosphorylation of monoacylglycerol. The exact pathways for the generation of 
LPA in ascites, saliva, seminal and other body fluids are yet to be fully delineated.  
Similarly, the mechanism for intracellular production of LPA is poorly understood. 
In ovarian and other cancer cells, LPA production can be stimulated by cell activation in 
response to phorbol esters [27], bombesin [27] and LPA itself [28, 29]. The activation of 
LPA production may involve multiple steps catalyzed by phospholipases, unlike the 
extracellular pathway where the precursors of LPA already preexist. In normal cells, the 
intracellular and extracellular LPA levels are tightly controlled by LPA synthesizing and 
metabolizing enzymes. Lipid phosphate phosphohydrolases (LPP) are a family of enzymes 
that catalyze the dephosphorylation of LPA [30-32]. These enzymes are membrane-
associated with extracellularly-facing catalytic site for clearance of LPA on the cell 
membrane. There is evidence that expression of these enzymes reduce LPA levels and 
compromise LPA-induced cellular functions [30]. In addition to dephosphorylation, LPA 
can also be converted to phosphatidic acid (PA) by acylation through the action of LPA 
acyl transferases (LPAAT) [33, 34]. 
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1.2 LPA Receptors and Signal Transduction 
LPA is a bioactive phospholipid and a potent mediator of a broad range of cellular 
responses. It promotes cell proliferation and survival; enhances cell migration and 
invasion; and induces changes in actin cytoskeleton and focal contact organization [3, 7, 
Fig. 1.1. Metabolism of bioactive LPA.  
LPA is formed extracellularly by diverse pathways including the deacylation of phosphatidic 
acid (PA) by PLA1/2 and the cleavage of lysophospholipids, predominantly LPC by 
autotoxin, which represent the major source of extracellular LPA. Overexpression of AGK in 
mitochondria was recently shown to promote the generation and release of LPA from 
monoacylglycerol (MAG) and diacylglycerol (DAG). [After Biochim Biophys Acta. 2007: 
1768(4):923-40] 
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29]. These responses culminate from the activation of a diverse array of signaling 
pathways initiated when LPA binds its receptors on the plasma membrane. At least seven 
LPA receptors have been identified. Based on their primary structure, LPA receptors are 
classified into two groups: the endothelial differentiation gene (Edg) group and the 
purinergic receptor family (P2Y) group. LPA1/Edg-2, LPA2/Edg-4 and LPA3/Edg-7 belong 
to the Edg family and share about 50-57% homology in their amino acids [35-38]. 
LPA4/P2Y9/GPR23 and LPA5/P2Y5 of the P2Y family of receptors are two novel LPA 
receptors structurally distant from the LPA receptors of the Edg family, sharing only 20-
24% homology with LPA1-3 [39, 40].  LPA has also been identified as a ligand for two 
additional orphan receptors GPR87 and P2Y10 of the P2Y family [41, 42]. The identities of 
these receptors as bona fide LPA receptors are yet to be thoroughly studied. 
LPA receptors are G protein coupled receptors (GPCRs). They elicit their activities 
by coupling to trimeric G proteins subunits, Gα and Gβγ [35-40]. Aberrant regulation 
GPCRs have been linked to numerous diseases including cardiovascular defects, diabetes, 
allergies and certain forms of cancer [43-46]. More than 30% of the drugs in current use 
target the inhibition of GPCRs [47, 48]. LPA GPCRs couple to diverse G proteins 
including Gi, Gq and G12/13 to initiate the activation of parallel yet interactive intracellular 
signaling cascades culminating in physiological responses. Activation of Gq  mediates the 
activation of phospholipase C (PLC) with subsequent hydrolysis of phosphatidylinositol 
biphosphate (PIP2) to  inositol trisphosphate (IP3), an activator of intracellular calcium 
release and diacylglycerol (DAG), that activates protein kinase C (PKC) [16, 49]. Gi 
mediates the inhibition of adenylate cyclase leading to downregulation of intracellular 
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cAMP. Gi or associated Gβ/γ subunit are also linked to activation of Ras and downstream 
mitogenic Ras/mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase 
(PI3K) [50, 51]. Activation of Ras-MAPK and PI3K are critical to LPA-induced cell-
proliferation, migration and survival [50, 52]. The effects of LPA on stress fibre formation 
and the cell cytoskeleton occur through the activation of G12/13/ RhoA [53]. 
Rapid internalization of receptor from the plasma membrane following ligand-
induced activation is one way of quenching LPA signals [54]. The mechanism of the 
metabolic fate of the receptor after internalization is not yet known. In addition to GPCRs, 
LPA may also have some intracellular targets including proliferator-activated receptor γ 
(PPAR-γ)  [55, 56]. PPAR-γ regulates the transcription of genes involved in glucose and 
fatty acid metabolism, adipocytes differentiation and inflammation process [57, 58]. LPA 
may be able to enter the cell in sufficient quantity and activate this intracellular receptor, 
suggesting its participation in intracellular signaling and cell functions. While 
overexpression studies have helped to understand the general functions of LPA receptors, 
the challenge remains as to the assignment of LPA receptor subtypes to specific signal 
transduction cascades and define their relative contribution to the multiple biological 
activities of LPA. 
 
1.3 Role of LPA in Tumor Biology 
Gene targeting and pharmacological inhibition of LPA receptor subtypes in mice 
and different cell types revealed diverse physiological and pathological roles for LPA 
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signaling. The Edg LPA receptors are differentially expressed in various tissues [59, 60]. 
LPA1 is most widely expressed and present in both normal and malignant cells. In contrast, 
expression of LPA2 is more restricted. LPA3 is barely seen in normal tissues [60]. Recent 
studies showed that, in ovarian and thyroid cancers, malignant transformation is associated 
with increased expression of LPA2 (and LPA3 in ovarian cancer) [61, 62]. LPA receptors 
are also overexpressed in many other cancer types including endometrioid, colon, and 
colorectal cancer [63-65]. These observations suggest that changes in LPA receptor 
expression during malignant transformation are intimately involved in carcinogenesis. 
Furthermore, increased expression LPA receptors also correlates with important cancer 
progression processes such as migration and metastasis in many cancer types [63-65]. 
Recent studies have demonstrated that the presence of LPA in intraperitoneal effusions of 
ovarian cancer patients may contribute significantly to the progression and aggressive 
characteristics of the malignant cells [7, 62, 66]. In addition, various ovarian cancer cell 
lines respond to LPA stimulation with increase in migration and invasion. The influence of 
LPA on various cellular processes is supported by its ability to regulate the expression of 
diverse genes. 
 
1.4 Regulation of Gene Expression 
The most fundamental task of any organism is the control of the expression of the 
thousands of genes harbored by its genome. Genes are segments of DNA that carry 
information necessary for the development and proper functioning of all living organisms. 
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A normal cell possesses the capacity to process in parallel, the many regulatory inputs 
received from within and without, into enormous regulatory outputs that are tissue specific. 
When a cell grows, it divides by replicating its DNA into two daughter cells, each having 
the same genetic information as the parent cell. Gene expression, the representation of this 
inheritable information from the sequence of bases of the DNA to functional forms, is a 
complex and tightly regulated process. Diverse functions and features are acquired by 
selectively expressing or repressing segments of the DNA. Although basal expression of 
certain genes occurs in a resting cell, the active expression or repression of many genes are 
signaled for by complex sets of molecules and processes within or external to the cell. 
Abnormal gene expression by malignant cells is a result of the circumvention of these 
regulatory signals.  
Microarray analysis of LPA-induced gene expression in an ovarian cancer cell line 
from our lab showed that LPA stimulated expression of many cancer-related genes (Table 
1.1). LPA can therefore modulate cellular responses of malignant cells by inducing 
expression of these targets genes including cytokines, proteases, cell adhesion molecules, 
proangiogenic factors and anti-apoptotic genes. The array of LPA-target genes continue to 
expand ascribing new roles for LPA in more physiological and pathological contexts. 
However, the mechanistic details of how LPA regulates the expression of many genes 
remain elusive. As described in Chapter 2 of this dissertation, we have focused on LPA-
induced expression of cyclooxygenase 2 (Cox-2) as a model to elucidate the mechanisms 
of gene regulation by LPA. 
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Table 1.1 Microarray analysis of some LPA-responsive genes in OVCAR3 cells 
7.2Defender against cell death
9.2Forkhead
Apoptosis
11.2V-ski
7.6Protein tyrosine phosphatase
5.4MAP Kinase phosphatase (MKP-2)
7.7Protein Tyrosine Kinase NET
Signaling Molecules
5.7Integrin alpha-3 subunit
17.6Fibronectin 1
Adhesion Molecules
13.8Urokinase Plasminogen Activator (uPA)
9.4Plasminogen Activator, tissue type (tPA)
Proteases
28.3GROα oncogene
13.2Interleukin 6 (IL-6)
31.5Interleukin 8 (IL-8)
Cytokines and Angiogenic Factors
Fold IncreaseGenes
 
 
 
1.5 Regulation of Transcriptional Activation 
Transcriptional activation represents an important point in the control of gene 
expression. Many transcription activators are formed by the interaction of several protein 
subunits some of which directly bind DNA or attach to bound complexes via non-covalent 
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interactions. Emerging evidence suggests that the influence of LPA on gene expression to 
a large extent involves activation of transcription factors [67-69]. With 10% of genes in the 
human genome coding for transcription factors, this group are the single largest family of 
human proteins (approx. 2600 members) [70, 71]. Transcription factors bind to 
unexpressed portion of the DNA mainly made up of specific sequences of regulatory 
modules. These modules contain distal enhancer elements, core or basal promoter elements 
and proximal promoter elements. The TATA element, located 25 base pair (bp) from the 
transcription start site and a pyrimidine-rich initiator (Inr) element found at the 
transcription start site, represent major modules of the core promoter element [72, 73]. 
Both elements can function independently or synergistically [73]. A cell responds to 
stimuli such as growth factors and hormones by turning off or on signaling cascades that 
usually peaks with activation of one or more transcription factors.  
Many transcription factors consist of one or more DNA binding domain (DBD) 
[74]. They also often possess a trans-activating domain (TAD) and/or a signal sensing 
domain (SSD) [75]. The DBD and TAD domains of a single transcription factor can 
function independently [74]. Transcription factors positively or negatively modulate the 
expression of their target genes. Therefore, a transcription factor can be an activator 
(promoting transcription) or a repressor (downregulating or suppressing transcription). 
Functionally, a transcription factor can either be constitutively-active (present in the cell all 
the time) or conditionally-active (requiring cell-specific or external signal for activation).  
The most important tumor suppressor gene is protein p53, a transcription factor 
activated following cellular stress [76, 77]. More than 40% of epithelial ovarian 
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carcinomas are known to harbor inactivating mutations in p53 gene [78, 79]. The presence 
of inactivating p53 mutation in many cancer types underscores the importance of the anti-
proliferative functions of this transcription factor. In fact, drug resistance in cancer therapy 
has been associated with p53 mutations [80-82]. Unlike p53, most of the other 
transcription factors known to play important roles in the proliferation and survival of 
cancer cells are either overexpressed or highly activated. Several studies have described 
the general mechanisms for the activation of common transcription factors including 
activator protein 1 (AP-1), signal transducers and activators of transcription (STATs), 
specificity protein 1 (Sp-1), CCAAT/enhancer binding proteins (C/EBPs) and nuclear 
factor-kappa light chain enhancer of B cells (NF-κB). However, specific information of 
how cellular context might modulate the activities of these proteins in many human 
malignancies including ovarian cancer is still lacking. Many LPA-target genes harbor 
binding sites for a common subset of transcription factors in their promoters, suggesting 
common mechanisms for their regulation by LPA (Fig. 1.2). Targeting pathways that 
activate these transcription factors remains an attractive option for the treatment of cancer. 
Mechanistic details of the activation of these transcription factors by LPA in ovarian 
cancer will promote better understanding of ovarian oncogenesis and may lead to 
identification of novel targets for treatments of ovarian cancer. 
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1.5.1 Activation of AP-1 family of Transcription Factors 
AP-1 proteins belong to the bZIP family, a group of protein that possesses a 
bipartite DNA-binding motif consisting of a basic region for DNA contact and a leucine 
zipper region for dimerization. AP-1 members include the Jun proteins (c-Jun, Jun B, Jun 
D), ATF and Fos proteins (c-Fos, FosB, Fra-1 and Fra-2) [83, 84]. These transcription 
factors play a central role in the regulation of gene expression and cell transformation. AP-
1 controls cellular processes such as differentiation, proliferation and apoptosis in response 
to a variety of stimuli including growth factors, stress, cytokines and bacterial and viral 
infections [84, 85]. AP-1 proteins interact with a TPA (12-O-tetradecanoylphorbol-13-
acetate) responsive element (TRE) TGAC/GTCA on the promoter and enhancer regions of 
Fig. 1.2. Representation of transcription factors response elements in the human Cox-2, 
IL-6 and uPA promoters  
Upstream location to the start site of transcription is indicated with numbers (not to scale). 
Black shapes represent binding site for indicated transcription factor. 
‐1‐500
IL‐6
‐1‐1000
Cox‐2
‐1‐1600
uPA C/EBP‐β
AP‐1
NF‐κB
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their target genes, and bind DNA after dimerization [86, 87]. Fos proteins though lacking 
DNA-binding domain, become transcriptionally active when they form heterodimers with 
other AP-1 components. In contrast, Jun proteins can form both homodimers and 
heterodimers though Jun-Fos heterodimers are more stable and therefore favored [88]. In 
fact, the re-introduction of c-Fos in F9 teratocarcinoma cells was shown to enhance the 
transcriptional and transforming properties of c-Jun and JunB [89, 90]. Dimers of AP-1 
proteins can stimulate or repress transcription. While c-Jun/c-Fos heterodimers are known 
transcriptional activators, Jun B/c-Fos complexes are mostly repressors of transcription 
[91-93]. Since c-Jun and c-Fos members vary significantly in their relative abundance in 
different cell types, a complex network of transcriptional regulators is formed when these 
proteins interact with family members and with additional proteins. AP-1 proteins dimerize 
efficiently with other transcription factors such as ATF/CREB family of proteins [94-96]. 
Nearly all AP-1 components have been implicated in tumor development and 
progression; and many of these proteins have also been shown to possess transforming 
potentials [97, 98]. The expression pattern of AP-1 proteins in tumors varies depending on 
tissue type [99-101]. For example, high expression levels of Fra-1 and Fra-2 are associated 
with metastatic cell lines such as mouse mammary adenocarcinoma CSML-100 [102, 103]. 
However, no detectable expression of c-Fos or Fos B was found in this cell type. In a 
closely associated weakly invasive and non-metastatic CSML-10, only c-Fos was detected; 
but the expression of c-Jun remained essentially the same in both cell lines [102]. 
Immunohistochemical studies using well differentiated endometrioid endometrial tumor 
samples showed significant correlation of high tumor grade or disease stage with 
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expression of c-Fos [101]. The same studies showed that the overexpression of c-Fos seem 
to substitute for the expression and perhaps the role of Fra-1 in non-endometriod tumors 
such as breast carcinomas. The role of various AP-1 components in other cancer types is 
inconclusive. For instance, reduced cell viability was observed in ovarian cancer cells 
overexpressing a dominant-negative form of c-Fos in the presence of non lethal doses of 
cisplatin, an anticancer drug [104]. However, another experimental system demonstrated 
that c-Fos protein levels in ovarian carcinoma cell lines correlate with response to 
paclitaxel therapy in nude mouse xenograft [105]. 
In many cell types, expression of AP-1 proteins is often temporally modulated in 
response to stimuli. As such, the functional activity of AP-1 in a particular cell is not only 
dynamic with respect to time but also a function of the differentiation state and 
environment of the cell. The DNA binding activity and transcriptional capacity of AP-1 
proteins are greatly affected by post-translational modifications particularly 
phosphorylation. The c-Jun N-terminal kinases (JNK or stress activated protein kinase 
SAPK), members of the MAPK family, are the mediators of phosphorylation of Jun family 
members [106] while a variety of proteins have been reported as putative c-Fos kinases 
including MEK5, RSK and p38 MAPKs [107-109]. c-Jun is phosphorylated by JNK at 
specific serine residues. In particular, phosphorylation of c-Jun at Serine 63 and 73 located 
within its transactivation domain increases its transactivation capacity [106]. Studies show 
that deacetylation of c-Jun by CBP, a histone deacetylase enhances the transcriptional 
activity by several folds [110, 111]. Further, the promoter of c-Jun harbors the binding 
sites of many transcription factors including AP-1 itself. Thus, agonist-induced c-Jun 
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transcription is often followed by an increase in the expression of c-Jun. This positive auto-
regulatory loop is a common phenomenon shared by many other AP-1 components [112-
114]. AP-1 target genes include MMPs [115], uPA [116], VEGF [117], CD44 [118], and 
Bcl-2 [119]. A subset of these genes responds to LPA stimulation in diverse cell types [12, 
62].  
 
1.5.2 Activation of C/EBP 
  The C/EBP family is made up of six members: C/EBP-α, C/EBP-β, C/EBP-γ, 
C/EBP-δ, C/EBP-ε, and C/EBP-ζ [120, 121]. With the exception of C/EBP-ε, and C/EBP-
ζ, this subfamily of transcription factors belong to the exclusive group of liver-enriched 
transcription factors having been first discovered in the liver. C/EBPs are also members of 
the bZIP family of proteins [121]. C/EBPs form homo- and heterodimers with family 
members and with other bZIP family of transcription factors including the AP-1 proteins c-
Jun and c-Fos [122, 123]. C/EBPs recognize a specific palindromic sequence in the major 
groove of DNA. It has been proposed that dimerization between two groups of leucine 
zipper proteins brings the basic amino acids of DNA binding domain into close proximity 
[120, 124, 125]. Hence C/EBPs dimerization is a prerequisite for DNA binding and dimers 
readily dissociate into monomers when not bound to DNA. The C/EBP proteins also 
contain activation and regulatory domains in the N-termini [125]. 
C/EBPs play important roles in cell proliferation and differentiation, liver 
regeneration, energy metabolism, tumorigenesis and other physiological processes [121, 
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126, 127]. Although tissue expression patterns of C/EBPs often overlap, there exist 
significant differences in the functions of each member of the family [128]. C/EBP-α-/- 
mice are neonatal lethal due to hypoglycemia and lack of stored liver glycogen, 
accentuating the role of C/EBP-α in glucose metabolism and terminal differentiation of 
adipogenesis and hematopoiesis [124, 129]. However, C/EBP-β-/- mice are viable with 
serious defects in hematopoiesis and immune system [130, 131]. In addition, these mice 
showed a defective female reproduction system [132]. The loss of fertility in C/EBP-β-/- 
mice underscores the involvement C/EBP-β in ovarian follicular development and corpus 
leteum formation, enhancing the effects of lutenizing hormone (LH/hCG) [132-134]. 
Importantly, C/EBP-β is preferentially expressed in endometrial adenocarcinoma and has 
been shown to be overexpressed in ovarian cancer. Its expression level highly correlates 
with progression of the disease [135]. 
In some cell systems, expression of C/EBP-β gene can be induced by inflammatory 
cytokines, steroid hormones and growth factors [122, 136]. The effects of these stimuli on 
C/EBP-β expression can be simple in some cellular context but complicated in others. 
Insulin is a classical modulator of C/EBP-β expression in the liver [127]. In a rat hepatoma 
cell line, co-stimulation with insulin resulted in attenuation of C/EBP-β mRNA expression 
induced by cytokines and dexamethasone, while on its own, insulin increased C/EBP-β 
mRNA [137, 138]. The mechanisms involved in the regulation of C/EBP-β expression in 
other tissues types are not fully understood. 
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There are 3 isoforms of C/EBP-β: liver-enriched activating proteins (LAP1 and 
LAP2) and liver-enriched inhibiting protein (LIP), a consequence of alternative translation 
initiation sites within the C/EBP-β mRNA (Fig. 1.2) [138, 139]. LIP lacks a transactivation 
domain. The dimerization of LIP with LAP leads to inhibition of LAP transcriptional 
activity; thus LIP functions as a naturally-occurring transcriptional inhibitory or dominant-
negative (DN) form of C/EBP-β. Cellular LIP/LAP ratio has been shown to be critical in 
cell-fate determination [140, 141]. 
 Apart from the differential expression of LAP and LIP, the transcriptional activity 
of C/EBP-β can be modulated by several other mechanisms including post-translation 
NH2 COOH
- + + +Transactivation C/EBP‐βLAP1
Basic 
Region
Leucine
Zipper
DNA 
Binding
Dimerization
C/EBP‐βLAP2- + + +Transactivation
C/EBP‐βLIP- + + +
Fig. 1.3. Isoforms of C/EBP-β 
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modifications, nucleo-cytoplasmic shuttling and direct protein-protein interaction between 
C/EBP-β and transcription factors of other classes [123, 142]. Phosphorylation of C/EBP-β 
at specific serine or threonine residues is an important event that often results in the 
increase in its transcriptional activity [121, 125, 126]. However phosphorylation at other 
sistes such as Serine 173, 223 and 240 may decrease its DNA binding activity [121,123, 
142]. The kinases that mediate the phosphorylation of C/EBP-β include PKA, PKC, 
Camodulin Kinase II and MAP kinase [125]. These kinases lie downstream of diverse 
signaling cascades including those of GPCRs. 
C/EBP-β can interact with other transcription factors including Sp1, AP-1 and NF-
κB to activate transcription. This feature is mediated by the leucine zipper and the DNA 
binding domains [123, 143]. Heterodimeriztion between C/EBP and other transcription 
factors could enhance transcription activity of individual dimer partners. The crosstalk 
could also bring about changes in target specificity. For example, CREB/ATF and C/EBP-
β heterodimer causes C/EBP-β to bind onto palindromic cAMP responsive elements 
(CREs) on the DNA rather than the CCAAT C/EBP binding sites resulting in regulation of 
different target genes [144]. The activation and involvement of C/EBP-β in LPA-induced 
gene regulation is the focus of work described in Chapter 3 of this dissertation. 
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1.5.3 Activation of NF-κB 
 NF-κB is a ubiquitous transcription factor that plays important roles in many 
physiological and pathological processes. It is a central mediator of several inflammatory 
responses and immune function. NF-κB is activated by a wide variety of stimuli including 
inflammatory cytokines (e.g. tumor necrosis factor TNF) and microbial pathogens (e.g. 
lipopolysaccharide LPS) that bind cell surface receptors [145, 146]. Other important 
activators of NF-κB are genotoxic stress, DNA damage, UV light, oxidative stress, 
chemotherapeutic drugs, phorbol esters, growth factors and physiologic mediators such as 
angiotensin II and PAF [145]. Abnormal regulation of NF-κB has been linked to several 
disease conditions including inflammatory and autoimmune diseases, septic shock, 
improper immune development, viral infection and cancer [147, 148]. 
 In vertebrates, the NF-κB family consists of five Rel protein subunits, so called 
because they all share a common N-terminal Rel homology domain (RHD). Rel proteins 
may be classified into two groups. The first group consists of RelA (p65), RelB and c-Rel 
[149]. These subunits possess within their structures a C-terminal transactivation domain 
(TAD) to promote transcription. The second group, p50 and p52 are synthesized from large 
precursor molecules p105/p50 (NF-κB1) and p100/p52 (NF-κB2) respectively and lack the 
TAD [149]. However, p105 and p100 contain a series of five to seven ankyrin repeats that 
blocks a nuclear localization signal within the RHD. Both of these precursor proteins are 
processed by cleavage to generate the mature transcription factors, p50 and p52.  
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 Rel proteins form homo- and heterodimers by employing a C-terminal Ig-like 
domain of about 100 amino acids within the RHD commonly called the dimerization 
domain (DimD). Twelve of the fifteen possible dimers are able to bind to a consensus 
sequence (5’-GGGACTTTC-3’) on DNA and effectively participate in gene transcription 
[150-152]. While some Rel dimers, such as RelA/p50 heterodimers are well known as 
transcriptional activators, some others particularly dimers lacking RelA, RelB or c-Rel 
such as a p50 and p52 homodimers are generally repressors of κB site transcription [151, 
153, 154]. In addition to nuclear localization, dimerization and DNA binding, the RHD 
also mediates the interaction with the inhibitors of NF-κB, the IκBs. These proteins, 
sometimes regarded in literature as inhibitory subunits of NF-κB, possess a similar ankyrin 
repeat domain as in p100 and p105. They however lack the RHD. IκBs include IκBα, 
IκBβ, IκBγ (derived from c-terminal domain of p100), ΙκBε IkBζ, Bcl-3, pp40 and avian 
fever viral protein p28.2 [155-157]. In unstimulated conditions, NF-κB is complexed with 
IκBs through the ankyrin repeat domain resulting in its sequestration in the cytoplasm 
(IκBζ is known to retain NF-κB in the nucleus), away from its target genes. 
 The importance of NF-κB in processes that require rapidly-acting primary 
transcription factors (“first responders”) such as inflammation is underscored by the fact 
that NF-κB activation does not require new protein synthesis [158]. There are two known 
pathways for activation of NF-κB in stimulated cells.  In the classical or canonical 
pathway, activating signal induces the degradation of IκB proteins. A typical activator of 
this pathway is TNFα. Upon ligand-induced TNF receptor activation, multiple signals near 
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the cell membrane converge at the IκB kinase (IKK) complex that consists of IKKα, IKKβ 
and IKKγ (or NEMO- “NF-κB essential modulator”). The IKK complex is activated by the 
interaction of NEMO with a Lys-63-linked polyubiquitinylated receptor-interacting protein 
1, RIP1, a serine-threonine kinase. Activated IKKβ phosphorylates IκBα at two serine 
residues, Serine 32 and Serine 36. This tags the NF-κB inhibitor for multiple 
ubiquitinylation with subsequent degradation by the 26S proteasome [159]. Previously 
concealed NF-κB nuclear localization signal becomes exposed targeting the dimer, usually 
p65/p50 to the nucleus for transcription. Interestingly, IκB itself is one of NF-κB target 
genes and its expression is upregulated following NF-κB activation. 
The alternate or non-canonical pathway of NF-κB activation involves IKKα rather 
than IKKβ of the IKK complex. This pathway is based on the processing of p100 
following cellular stimulation by cytokines such as lymphotoxin β (LT-β), B cell 
activating factor (BAFF), CD40 ligand and viruses including the Epstein-Barr virus (EBV) 
[160]. Signal-induced post-translational stabilization of NF-κB inducing kinase (NIK) 
causes the protein to interact with a homodimer of IKKα thereby activating the latter.  A 
key point in this pathway is IKKα phosphorylation of p100, an event that leads to its 
polyubitinylation and proteasomal degradation of the C-terminus of the protein. The 
remnant portion, p52 continues to interact with RelB, now as a transcriptionally-active 
heterodimer that quickly moves into the nucleus. Beside stimulus-specific activation of 
either the classical or alternate pathway, a dynamic interaction of different NF-κB dimers 
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with specific gene promoters provides a critical control of the expression of NF-κB target 
genes [152]. 
In addition to IκB-dependent activation the NF-κB, diverse post-translational 
modifications serve as alternatives to regulate NF-κB activity. p50, an important partner of 
the most-studied NF-κB dimer RelA/p50, is regulated through processing of its precursor, 
p105. Similar to p100, stimulus-induced phosphorylation of p105 results in its 
polyubiquitinylation and subsequent proteolytic degradation to p50. The DNA binding 
activity of p50 has also been shown to be enhanced by phosphorylation of Serine 337 
located within its RHD domain [161]. p65 (RelA) can be phosphorylated by several 
protein kinases at specific residues and this inducible phosphorylation of p65 is often used 
as readout of NF-κB activation. A well-studied phosphorylation site is Serine 536 
catalyzed by IKKα/β, IKKε or TBK1 (TANK binding kinase 1) [162-164]. Although they 
share sequence homology with IKKα/β, IKKε and TBK1 are not part of the IKK complex. 
Phosphorylation of p65 at Serine 536 impairs its interaction with IκBα and increases its 
nuclear accumulation. However, whether Serine 536 phosphorylation of p65 is required for 
transcription remains controversial [165-167].  Other site-specific phosphorylation of p65 
at serine residues includes Serine 435 (by camodulin kinase IV, CaMKIV), Serine 468 (by 
IKKβ, IKKε and GSK-3β) [168] and Serine 276 (by catalytic subunit protein kinase A, 
PKAc) [169]. While phosphorylation of p65 at these residues are known to increase its 
transactivation potential, phosphorylation of threonine residues have been shown to 
suppress the activity of NF-κB. p65 phosphorylation of C-terminal Threonine 435 and 
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Threonine 505 is induced by ARF tumor suppressor, p14ARF in a p53-independent 
manner [170, 171]. Threonine 505 phosphorylation causes p65 to interact with histone 
deactelylase 1 (HDAC1), which greatly inhibits p65 transactivation. The phosphoryation 
of p65 is often the prerequisite for other post-translation modifications such as 
ubiquitinylation and acetylation that regulate the activity of the protein [172, 173]. 
Acetylation, like most phosphorylation events often results in enhanced activity of NF-κB 
[174].  
 
1.6 Crosstalk between GPCRs and Receptor Tyrosine Kinases (RTKs) 
Many transcription factors including those described in the preceding sections are 
substrate for molecules downstream of GPCR-induced signaling cascade, particularly 
kinases. For example, Gq-dependent activation of IKK with subsequent activation of NF-
κB has been described in many systems [175, 176]; and ATF-2 a member of AP-1 family 
is a substrate for p38/MAPK and the JNK/SAPKs, downstream effectors of MAPK [177]. 
The stimulation of  MAPK pathway via pertussis-toxin sensitive Gi represents a major 
signaling event downstream of LPA GPCRs. Gi-mediated activation of Ras seems to occur 
through a tyrosine kinase (TK)-dependent manner [178, 179]. The intracellular TK linking 
Gi signal to Ras activation has not been identified. Some studies suggest receptor tyrosine 
kinase (RTK), particularly epidermal growth factor receptor (EGFR), could serve the role 
[180, 181]. Indeed, many biological functions of GPCRs are known to depend on EGFR 
[181, 182]. Furthermore, emerging evidences suggest that some ligand-induced RTK 
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signaling may also require the cooperation of GPCRs [183]. The current dogma for the 
crosstalk between GPCRs and RTKs suggests that GPCR ligands such as LPA activate 
cellular responses through transactivation of EGFR or other highly expressed RTK [184]. 
The so-called transactivation model is not consistent with LPA stimulation of EGFR 
phosphorylation and activation or with LPA induction of proteolytic release of EGFR 
ligands such as EGF or HB-EGF in certain cellular systems [180, 185, 186]. However, 
recent evidence suggests that these two receptor types independently control different 
pathways leading to Ras activation in response to LPA. Background EGFR activity is 
necessary for basal nucleotide exchange on Ras, whereas the LPA receptor controls an 
inducible exchange activity [187, 188]. Thus, activation of Ras by LPA involves two 
parallel inputs: one directly from GPCR and the other signal from basal EGFR, a mode of 
action differing from the transactivation model [187, 189].   
The work described in Chapters 3 and 4 took advantage of LPA-induced activation 
of transcription factors as readout to analyze the role of RTKs in LPA regulation of gene 
expression. Our results indicate that LPA-induced activation of AP-1 and C/EBP-β 
requires an input from EGFR while activation of NF-kB by LPA is independent of EGFR 
activity. The differential requirement of EGFR for activation of different transcription 
factors are underlied by EGFR-dependent or independent G proteins signaling cascades 
involved in activation of these transcription factors. 
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CHAPTER 2 
REGULATION OF CYCLOOXYGENASE-2 EXPRESSION BY LPA: A 
PARADIGM OF LPA-INDUCED GENE EXPRESSION  
 
Part of the work presented in this chapter has been published in FASEB Journal 22: 2639-
2651 (2008).  
 
2.0 Abstract 
Cyclooxygenase-2 (Cox-2) is a key enzyme in the biosynthesis of prostaglandin 
(PGE) and thus functions as a critical mediator of inflammation. In addition to this well-
established role, Cox-2 is implicated in the pathogenesis of human malignancies including 
colon, breast and skin cancers. The role of Cox-2 and the mechanism for its regulation in 
ovarian cancer are poorly understood. In the current study, we demonstrated that LPA, a 
previously identified lipid mediator of ovarian cancer, induced expression of Cox-2 in 
ovarian cancer cell lines. Treatment of cells with LPA resulted in a rapid and robust 
accumulation of PGE2 in culture supernatants, indicating that LPA-induced Cox-2 
expression leads to PGE2 synthesis and release. We downregulated LPA receptors 
expression with siRNA and found that only a subset of LPA receptors participate in LPA-
induced Cox-2 expression. The effect of LPA involves both transcriptional activation and 
post-transcriptional enhancement of Cox-2 mRNA stability. The consensus sites for C/EBP 
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in the Cox-2 promoter were essential for transcriptional activation of Cox-2 by LPA. The 
NF-κB and AP-1 transcription factors commonly involved in inducible Cox-2 expression 
were dispensable. Dominant negative form C/EPB-β inhibited LPA-induced activation of 
the Cox-2 promoter and expression. The RNA stabilization protein HuR bound to and 
protected Cox-2 mRNA in LPA-stimulated cells, indicating an active role for HuR in 
sustaining Cox-2 induction during physiological responses to LPA 
 
2.1 Introduction 
LPA is a naturally occurring phospholipid mediator of diverse biological activities 
[3, 7, 29, 190]. It is produced by activated platelets during coagulation and thus is a normal 
constituent of serum [14]. At least seven G protein-coupled receptors (GPCRs) of LPA 
have been identified. The LPA1/Edg2, LPA2/Edg4 and LPA3/Edg7 receptors are members 
of the endothelial cell differentiation gene (Edg) family and share 50-57% homology in 
their amino acid sequences [36-38]. LPA4/P2Y9/GPR23 and LPA5/P2Y5 of the P2Y family 
of receptors are two novel LPA receptors structurally distant from the LPA receptors of the 
Edg family, sharing only 20-24% homology with LPA1-3 [39, 40].  More recently, LPA has 
also been identified as a possible ligand for two additional orphan receptors GPR87 and 
P2Y10 [41, 42]. In addition to these cell surface GPCRs, LPA also been shown to bind and 
activate the peroxisome proliferator–activated receptor γ (PPARγ) which plays critical 
roles in controlling fat and energy metabolism [55].  
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A number of G-protein-dependent signaling cascades have been identified as 
potentially mediating the actions of LPA e.g. stimulation of phospholipases C and D [16, 
49], inhibition of adenylate cyclase [49], activation of Ras and the downstream mitogen-
activated protein kinase (MAPK), and tyrosine phosphorylation of focal-adhesion proteins 
[50, 52]. Activation of these signaling events downstream of LPA receptors culminates in 
cell morphological changes, cell growth, survival and migration [50, 51]. Recently, we and 
others described that LPA is also a potent modulator of gene expression, in particular, the 
genes involved in the inflammatory processes and carcinogenesis [9, 62, 191-195]. The 
effect of LPA on gene expression has been mainly investigated in human ovarian cancer 
cells wherein both LPA receptors (LPA2 and LPA3) and LPA levels are found to be 
upregulated [4, 62]. A number of inflammatory cytokines, angiogenic factors and 
oncoproteins such as interleukin-6 (IL-6) [9, 191], interleukin 8 (IL-8) [9], vascular 
endothelial growth factor (VEGF) [193], urokinase plasminogen activator (uPA) [194] and 
cyclooxygenase-2 (Cox-2) [195] have been reported to be induced induced by treatment of 
ovarian cancer cells with LPA .  
Cyclooxygenases are involved in biosynthesis of prostaglandins (PGE) from 
arachidonic acid (AA) [196]. Cox-1 is constitutively expressed in most cell types while 
Cox-2 is an inducible form, upregulated by pro-inflammatory cytokines, stress and growth 
factors [196]. In addition to the well established role in inflammation, Cox-2 has been 
implicated in human carcinogenesis, particularly in cancers of the colon, breast and skin 
[196-198]. Pharmacological suppression of Cox-2 activity with specific inhibitors reduces 
the number and size of adenomas in patients with familial adenomatous polyposis and 
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prevents colon cancer development [196-198]. The role of Cox-2 in the development of 
other types of malignancies including ovarian cancer is more controversial. Recent 
evidence indicates that a majority of ovarian tumors including serous, endometroid, clear 
cell and mucinous carcinomas and borderline tumors display positive Cox-2 
immunoreactivity with approximately 70% overall cases showing moderate to high levels 
of expression [195]. LPA, a lipid mediator present in ascites of ovarian cancer patients 
[62], is a potent stimulus of Cox-2 expression in ovarian cancer cell lines [195]. Because 
both expression of LPA receptors and LPA levels are elevated in ovarian cancer [62], the 
ability of LPA to induce Cox-2 gene expression may reflect a physiological role for LPA 
in regulation of prostaglandins in ovarian tumor cells in vivo. In addition, genetic deletion 
of the LPA3 receptor in mice leads to a delayed implantation and defective embryo spacing, 
associated with reduced uterine expression of Cox-2 mRNA in the LPA3-deficient female 
mice [199], suggesting that LPA is an endogenous regulator of prostaglandin generation in 
the uterus crucial to mammalian reproduction.  
Despite the prominent role of LPA signaling in regulation of Cox-2 [195, 199, 
200], little is known about the LPA receptors, intracellular signaling pathways and 
transcription factors involved in the process. The results presented in the current work 
demonstrate that LPA-induced expression of Cox-2 involves both transcriptional and 
posttranscriptional regulation. The transcriptional activation of Cox-2 by LPA is mediated 
primarily by the CCAAT enhancer-binding protein (C/EBP) transcription factor 
independently of other transcription factors such as NF-κB and AP-1 commonly involved 
in inducible Cox-2 expression. Further, we demonstrated that the transcriptional 
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stimulation is reinforced by posttranscriptional protection of Cox-2 mRNA stability 
mediated by the RNA binding protein HuR, leading to sustained induction of Cox-2 in 
LPA-treated cells. 
  
2.2 Materials and Methods 
 
Materials 1-Oleoly (18:1) LPA and sphingosine 1 phosphate (S1P) were obtained from 
Avanti Polar Lipids, Inc. (Alabaster, AL). Prior to use, these phospholipids were dissolved 
in PBS containing 0.5% fatty acid-free bovine serum albumin (BSA). BSA, Fugene 6 and 
protease inhibitor cocktail tablets were purchased from Roche (Indianapolis, IN). The 
PGE2 EIA kit, NS-398 and AA were purchased from Cayman Co. (Ann Arbor, MI). [3H]-
AA and [32P]-dCTP were purchased from Perkin Elmer (Boston, MA) and Amersham 
Biosciences (Piscataway, NJ), respectively. Plasmid DNA was purified using the endo-free 
purification kit from Qiagen (Valencia, CA). Luciferase assay reagents were obtained from 
Promega (Madison, WI). GW9662, and pharmacological inhibitors of MAPKs were from 
Calbiochem (San Diego, CA). Pertussis toxin (PTX) was purchased from List Biological 
Laboratories, Inc. (Campbell, CA). All oligonucleotides and primers were synthesized by 
Operon Biotechnologies, Inc (Huntsville, AL). Phospho-specific antibodies for 
phosphorylated ERK, JNK, CEBP-β and anti-tubulin α/β antibodies were obtained from 
Cell Signaling (Danvers, MA). The monoclonal antibodies against Cox-2 and HuR and a 
polyclonal antibody against Cox-1 were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA). Insulin, TRIzol and cell culture medium were obtained from Invitrogen Inc. 
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(Carlsbad, CA). Bovine fetal serum was from Biomeda (Foster City, CA). Insulin-like 
growth factor I (IGF-I) was from Upstate Biotechnology (Lake Placid, NY). Hepatocyte 
growth factor (HGF) was from R & D systems (Minneapolis, MN). Epidermal growth 
factor (EGF), AG1478 and anti-β-actin monoclonal antibody were obtained from Sigma-
Aldrich (St. Louis, MO). 
 
Plasmids The C/EBP-β, liver-enriched transcriptional activator protein 1 (LAP1) and 
LAP2 expression vectors were kindly provided by Dr. L. Sealy (Vanderbilt University 
School of Medicine) [139, 201]. The expression of C/EBP-β from these vectors in 
transfected cells was confirmed by immunoblotting. The dominant negative form of 
C/EBP-β, LIP (liver-enriched inhibitory protein), [202] was cloned into pcDNA3.1 by RT-
PCR amplification of a 444 bp cDNA fragment of C/EBP-β from Caov-3 cells (see primer 
details in Table 2.1). The structure of pcDNA3-LIP was confirmed by automatic 
sequencing and immunoblotting analysis of expression of the short, truncated form of 
C/EBP-β (21 kD) [201] in transfected cells. 
 
Cell Culture The sources of ovarian cancer cell lines used in the study were described 
previously [9, 192]. These cells were cultured in RPMI medium supplemented with 10% 
FBS, 100 units/ml penicillin and 100 μg/ml streptomycin. All cell lines were frozen at 
early passages and used for less than 10 weeks in continuous culture.  
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Western Blot Cells were lysed in SDS sample buffer or in ice-cold X-100 lysis buffer [1% 
Triton X-100, 50 mM HEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 
10% glycerol, 100 mM NaF, 10 mM Na PPi, and protease inhibitor cocktail]. Total cellular 
proteins were resolved by SDSPAGE, transferred to Immun-Blot membrane 
[poly(vinylidene difluoride)] (BIO-RAD, Hercules, CA), and immunoblotted with 
antibodies following the protocols of manufacturers. Immunocomplexes were visualized 
with an enhanced chemiluminescence detection kit from Amersham (Piscataway, NJ) 
using the horseradish peroxidase–conjugated secondary antibodies (Cell Signaling, 
Danvers, MA). 
 
Quantitative determination of PGE2 in culture supernatants Ovarian cancer cell lines 
were plated in 6-well plates and grown to 60% confluence in complete medium. The cells 
were starved for 24 hours before stimulation with LPA or vehicle for the specified periods 
of time. The levels of prostaglandins E2 (PGE2) present in culture supernatants were 
quantified using the PGE2 EIA kit. 
 
AA release Ovarian cancer cell lines were plated in 6-well plates and grown to 60% 
confluence in complete medium. The cells were labeled with 1 μCi [3H] AA/well in 2 ml 
of serum-free DMEM for 20 hours. The cells were washed 3 times with DMEM and 
incubated with DMEM containing 0.1% fatty acid-free BSA (DMEM+BSA) for 3 hours. 
The cells were then refed new DMEM+BSA and incubated with LPA or ATP for the 
indicated periods of time. The cells were dissolved in 2 ml of 0.2 N NaOH overnight. The 
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radioactivity in the supernatants and cells was determined by scintillation spectrometry. 
The AA release was presented as percentages of the activity present in medium versus the 
total labeling in both medium and cells.  
 
Northern blot and mRNA stability assays Total cellular RNA was extracted from cell 
lines using the TRIzol reagent following the instruction of the supplier. RNA samples were 
electrophoresed on agarose gel containing formaldehyde, stained with ethidium bromide, 
and transferred to N+ hybrid nylon. RNA was immobilized with UV cross-linking, 
prehybridized and hybridized to 32P-labeled cDNA probes at 65oC overnight in a 
hybridization buffer (1% BSA, 0.5 M NaH2PO4, 1 mM EDTA, 7% SDS, 10 μg/ml salmon 
sperm DNA). The cDNA of the human Cox-2 and LPA receptors genes were isolated by 
RT-PCR amplification from Caov-3 cells. The 32P-deoxy-CTP-labeled DNA probes were 
prepared using the High Prime labeling system (Roche). Equal loading of RNA samples 
was confirmed by rehybridization to the cDNA of 18S rRNA (ATCC). To determine Cox-
2 mRNA stability, Caov-3 cells were treated with or without 10 μM LPA for 6 hours 
before actinomycin D (5 μg/ml) was added to stop new RNA synthesis. Total cellular RNA 
was isolated from the cells using TRIzol at 0, 2, 4 and 6 hr after addition of actinomycin D. 
Reverse transcription was performed to synthesize single stranded cDNAs using 
ThermoScript (Invitrigen). The relative levels of Cox-2 mRNA were quantified by qPCR 
using the human Cox-2 specific probe and the TaqMan system from Applied Biosystems 
(Foster City, CA).  
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siRNA - The human LPA1-3 and LPA5 receptor SMARTpool siRNAs and the Bcl10 
siRNAs and the non-target control siRNA (see Table 2.1) were purchased from Ambion 
(Austin, TX). The specific siRNA or non-target control siRNA (2.25 μg) was transfected 
into ovarian cancer cell lines (1.25 x106 cells) with Amaxa nucleofector II (Kit T, Program 
T32). The transfected cells were cultured in 6-well plates in complete medium. After 48 
hours, the cells were starved in serum-free RPMI 1640 and stimulated with LPA for 6 or 
12 hours for Cox-2 induction. RNA was isolated from parallel cultures for RT-qPCR 
analysis to determine the efficiency of siRNA knockdown.  
 
The reporter vectors and luciferase assays The proximal sequence (–980 to +15) of the 
human Cox-2 gene promoter [202] was cloned from the genomic DNA of Caov-3 cells by 
PCR amplification and inserted into the pGL2-Basic vector (Promega) and verified by 
automatic sequencing. The 7.2 kb Cox-2 promoter fragment was kindly provided by Dr. 
TM McIntyre (Cleveland Clinic Foundation) [202] and were cloned into the pGL2-Basic 
vector. Ovarian cancer cell lines were seeded in 6-well plates and grown to 30-40 % 
confluence before transfection with the luciferase vectors using Fugene 6 (Roche) or 
TransIT-TKO (Mirus Bio Corp., Madison, WI) according to the instructions of the 
manufacturers. About 48 hours after transfection, the cells were starved for 24-36 hours 
before stimulation with LPA or vehicle for 6 hours. Cell extracts were prepared and 
assayed for luciferase activity using the luciferase assay kit from Promega. The luciferase 
activity was normalized on the basis of the activity of cotransfected β-galactosidase 
reporter driven by the cytomegalovirus promoter (pCMVβ-gal).  
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Table 2.1 Plasmids and Primers 
Target Gene Primers 
Cox-2-1kb-Luc 5’-TTTAGCGTCCCTGCAAATTCTGGC-3’(SENSE)  
5’-CGCTCACTGCAAGTCGTATGACAA-3’ (ANTISENSE). 
Cox-2 cDNA 5’-AGATCATAAGCGAGGGCCAGCTTT-3’ (SENSE)  
5’-ACTTTCTGTACTGCGGGTGGAACA-3’ (ANTISENSE). 
LPA1 cdna 5’-TGGTGGTCATTGTGGTCATCTGGA-3’(SENSE)  
5’-AAGGTGGCGCTCATTTCTTTGTCG-3’ (ANTISENSE). 
LPA2 cdna 5’-TACAACGAGACCATCGGCTTCTTC-3’(SENSE)  
5’-GCAAGAGTACACAGCATTGAC-3’ (ANTISENSE). 
LPA3 cdna 5’-AATTGCCTCAACATCTCTGCC-3’(SENSE)  
5’-TATGTACTGGCTGCCTGTGTCACT-3’ (ANTISENSE). 
LPA4 cdna 5’-CGCCACCATGGACTACAAG-3’(SENSE)  
5’-AAGAGGCTGAAATACCGCCACTGA-3’ (ANTISENSE). 
LPA5 cdna 5’-CAGAGCAACACGGAGCACAGGT-3’(SENSE)  
5’-GATGCAGCTGCCGTACATGTTCATCT-3’ (ANTISENSE). 
LIP 5’-GGAATCAAGCTTGGCGCACATGGCGGCG-3’ (SENSE)  
5’-GCAATACTCGAGCGCTAGCAGTGGCCGGAGG-3’ (ANTISENSE). 
GAPDH 5’-TGAAGGTCGGAGTCAACGGATTTGGT-3’(SENSE)  
5’-CATGTGGGCCATGAGGTCCACCAC-3’ (ANTISENSE). 
Cox-2 3’ UTR-T7 5’-TCCTAATACGACTCACTATAGGGAAGTCTAATGATCATATTTAT-3’ (SENSE) 
5’-GCTATTTAGGTGACACTATAATCATGGAAGATGCATTG-3’ (ANTISENSE). 
Cox-2 484 cdna fragment 5’-TGTTCCACCCGCAGTA-CAGAAAGT-3’ (SENSE)  
5’-GCGGGAAGAACTTGCATTGATGGT-3’ (ANTISENSE). 
HuR siRNA 5’- GGAUGAGUUACGAAGCCUGtt -3’ (SENSE)  
5’- CAGGCUUCGUAACUCAUCCtg -3’ (ANTISENSE). 
Bcl10 siRNA1 5’- GGAAAACCCAAAAGGUCUGtt -3’ (SENSE)  
5’- CAGACCUUUUGGGUUUUCCtg -3’ (ANTISENSE). 
Bcl10 siRNA2 5’- GGUCUGGACACCCUUGUUGtt -3’ (SENSE)  
5’- CAACAAGGGUGUCCAGACCtt -3’ (ANTISENSE). 
Bcl10 siRNA3 5’- GCAUACUUCUAGGAUAGCUtt -3’ (SENSE)  
5’- AGCUAUCCUAGAAGUAUGCtt -3’ (ANTISENSE). 
Non-target control siRNA 5’- AGUACUGCUUACGAUACGGtt -3’ (SENSE)  
5’- CCGUAUCGUAAGCAGUACUtt -3’ (ANTISENSE). 
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Chromatin Immunoprecipation (ChIP) Assay - Cells were fixed by cross-linking the 
chromatin with 1% formaldehyde for 5 min, cells and then were scraped with a rubber 
policeman and collected by centrifugation. The cells were lysed gently with a hypotonic 
buffer [10 mM Tris-HCl (pH 7.4), 10 mM KCl, 3 mM MgCl2, 0.5% NP-40], and then 
sonicated six times, 15 s each with 1-min intervals on ice by using a Sonic Dismembrator 
(Fisher Scientific). The average fragment size was 600 bp under these conditions. An equal 
amount of chromatin was incubated with at least 5 µg of either C/EBP-β-specific 
immunoglobulin G (IgG) or normal mouse IgG (Santa Cruz Biotech) at 4°C overnight. IP 
products were collected after incubation with protein G-coated sepharose beads 
(Amersham). The beads were washed and protein-DNA complexes were eluted and then 
cross-links were reversed by incubating at 65oC in the presence of 0.2M NaCl. After 
digestion of proteins with Proteinase K (0.5 μg/ml) at 55oC for 1 hour, DNA was purified 
by Qiagen PCR purification columns according to manufacturer’s instruction. Purified 
DNA from the input and IP samples were subjected to PCR with Cox-2 promoter specific 
primers and analyzed by agarose gel electrophoresis. 
 
Deletion and site-directed mutagenesis - The unique AP-1-like site at around –577 was 
deleted from the pGL2-Cox2-1kb-Luc by restriction digestion with Af1III followed by re-
circulation of the plasmid. The consensus sequences of NF-κB and C/EBP transcription 
factors present within –980-+15 of the Cox-2 promoter in pGL2-Cox2-1kb-Luc were 
mutated into inactive sequences using site-directed mutagenesis kits from Stratagene 
(Cedar Creek, TX). The distal NF-κB site GGGGATTCCCTG was changed to 
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CGTCATTCCCTG and the proximal NF-κB site GGGGACTACCCC mutated to 
GGTCACTACCCC. The distal C/EBP site GCCTTTCTTAAC was mutated to 
GCCCCTATTAAC and the proximal one GGCTTACGCAAT converted to 
GACTTACGCTCT. The desired deletion and mutation of these binding sites for AP-1, 
NF-κB and C/EBP were confirmed by automatic sequencing before the plasmids were 
used for luciferase assays.  
 
Binding of Cox-2 transcripts with HuR in vitro and in vivo To assess the interaction of 
HuR with Cox-2 mRNA, the 3’ un-translated region (3’-UTR) of Cox-2 mRNA (375 bp 
from nt 1950-2325, NM_000963) was reversely transcribed and PCR amplified from 
Caov-3 cells using primers containing the T7 promoter sequences (Table 2.1). The PCR 
product was purified and utilized as a template for in vitro transcription. The transcripts 
equivalent to the 3’-UTR of Cox-2 mRNA was synthesized and labeled with biotin-11-
CTP by transcription from the T7 promoter using in vitro transcription kit (Promega). 
Lysates from control and LPA-treated cells were incubated with the biotinylated Cox-2 3’-
UTR transcripts in 1X binding buffer [10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 250 mM 
NaCl, 0.5% Triton X-100] for 30 min at room temperature. The binding complexes were 
isolated with paramagnetic streptavidin-conjugated Dynabeads (Invitrogen) and washed 
thoroughly with PBS followed by Western blotting analysis of HuR. To assess the 
association of HuR with Cox-2 mRNA endogenously, Caov-3 cells treated with or without 
LPA were harvested in PBS by scraping from dishes, pelleted and resuspended in 
polysome lysis buffer containing 100 mM KCl, 5 mM MgCl2, 10 mM Hepes (pH 7.0), 
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0.5% NP-40, 1 mM DTT, 100 U/ml RNaseOUT (Promega), and the complete protease 
inhibitor cocktail (Roche). For immunoprecipitation, 1,500 μg cellular proteins were 
diluted with 700 μl NT2 buffer [50 mM Tris (pH 7.4), 150 mM NaCl, and 1 mM MgCl2, 
0.05% NP-40, 5% fatty acid-free BSA, 1 mM DTT, 200 units/ml RNaseOUT and 15 mM 
EDTA] and incubated for 2 hours with 7.5 μg anti-HuR antibody or an IgG1 isotype 
control antibody. The immunocomplex was incubated for 1 hour with protein A Sepharose 
beads (GE Biosciences), and washed thoroughly with ice-cold NT2 buffer. After digestion 
of proteins present in the beads with Proteinase K (0.5 mg/ml) at 55oC for 20 min, the 
bead-free supernatants were extracted with phenol/chloroform and precipitated with 0.3 M 
NaAc, 150 μg/ml glycogen and 2.5 volumes of 100% ethanol. The precipitates were 
dissolved in 15 μl of nuclease-free water. Potential contamination with genomic DNA was 
removed using the DNA-free™ DNase Treatment & Removal kit (Ambion). Reverse 
transcription was performed on 5 μl of the samples with the ThermoScript kit (Invitrogen) 
followed by PCR amplification of a fragment of 481 bp close to the 3’ UTR of Cox-2 
mRNA.  
 
Statistics All numerical results were presented as mean ± SD. The statistical significance 
of differences was analyzed using Student's t-test, where P<0.05 was considered 
statistically significant. 
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2.3 Results 
 
2.3.1 LPA induces Cox-2 protein expression in ovarian cancer cells  
Several studies have shown that LPA induces expression of Cox-2 in various cell 
types including renal mesangial cells and colon and ovarian cancer cells [195, 200, 203]. 
However, the molecular mechanism regulating Cox-2 gene expression in response to LPA 
is poorly understood. LPA induced robust and sustained expression of Cox-2 protein in 
several ovarian cancer cell lines examined, with the most striking effect seen in Caov-3 
and OVCA-429 cells (Fig. 2.1).  
 
 
 
 
 
Fig. 2.1. LPA induces expression of Cox-2 protein in various ovarian cancer cell lines. 
The ovarian cancer cell lines were starved and stimulated with 10μM or indicated 
concentrations of LPA for 6 hr. The cells were lysed in SDS sample buffer and analyzed by 
immunoblotting for Cox-2. Re-blotting for β-actin was included to show equal loading 
among samples. 
Cox-2
β-actin
- +        - +        - +        - 5 μM 10 μM - + LPA
OVCA429      Dov-13          2780cp         OVCA433              Caov-3
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We chose the most responsive Caov-3 and OVCA-429 cells for further 
characterization. In both cell lines, the effect of LPA was detectable at sub-micromolar 
concentrations and the maximum effect was achieved with 1-10 μM of LPA (Fig. 2.2 A 
and B). Upon treatment with LPA, Cox-2 levels increased significantly within 1 hour and 
peaked at 12 hours (Fig. 2.2 A and B). LPA did not affect Cox-1 expression at early hour 
points. We observed a slight increase in Cox-1 in Caov-3 cells only after prolonged 
incubation with LPA for 12-18 hours (Fig. 2.2 A), likely reflecting an indirect effect of 
LPA. When Caov-3 cells were cultured in complete medium without starvation, LPA 
remained capable of stimulating Cox-2 expression (Fig. 2.2 C). However, the basal 
expression of Cox-2 was higher in unstarved cells and the LPA-mediated induction was 
weaker compared to that achieved in serum-starved cells (Fig. 2.2 C).  
We next compared the effects of LPA, FBS, S1P and the peptide growth factors 
EGF, HGF, and IGF-1 on Cox-2 expression in Caov-3 cells (Fig. 2.2 D). FBS was able to 
stimulate a prominent increase in Cox-2 protein. LPA is a component of FBS [14, 62, 190] 
and may account for the ability of FBS to drive Cox-2 expression. Interestingly, EGF, 
HGF and S1P only weakly stimulated Cox-2 expression (Fig. 2.2 D). The poor response to 
S1P suggests that induction of Cox-2 is specifically linked to certain GPCRs and is not a 
general outcome of GPCR activation.  
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Fig. 2.2. LPA is preferred in the induction of Cox expression in ovarian cancer cell 
lines. 
The ovarian cancer cell lines were starved and stimulated with different concentrations of 
LPA for the indicated periods of time or 6hr. The cells were lysed in SDS sample buffer and 
analyzed by immunoblotting for Cox-2. Re-blotting for Cox-1, α/β tubulin or β-actin was 
included to show equal loading among samples. The effect of LPA (10 μM, 6 hr) on Cox-2 
expression was also compared with that of S1P (5 μM), EGF (50 ng/ml), FBS (5%), and 
HGF (20 ng/ml) (C). The effect of LPA (10 μM, 6 hr) was also compared between serum-
starved cells and unstarved cells (D). 
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2.3.2 LPA induces PGE2 production and AA release  
We examined whether LPA-induced Cox-2 enzyme is functionally active, 
contributing to biosynthesis and release of PGE2. As shown in Fig. 2.3, LPA treatment 
strongly increased PGE2 levels in culture supernatants in a dose-dependent manner. LPA 
treatment led to significant release of AA (Fig. 2.4 A), supplying substrate for production 
of PGE2 in LPA-stimulated cells. Further, addition of exogenous AA (10 μM) to 
unstimulated Caov-3 cells also resulted in significant PGE2 generation (Fig. 2.4 B), 
suggesting the cells could utilize the basal Cox enzyme(s) to synthesize PGE2 when the 
substrate becomes available.  
 
 
Fig. 2.3. LPA induces release of PGE2 in ovarian cancer cell line, Caov-3. 
Caov-3 cells were treated with the indicated concentrations of LPA for 5, 10 or 15 hr before 
PGE2 levels in culture supernatants were quantified using the PGE2 EIA kits. The results are 
mean ± SD of triplicates, representative of three independent experiments. The statistically 
significant differences were indicated with asterisks. 
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We also observed a synergism between LPA treatment and exogenous AA in 
stimulation of PGE2 production (Fig. 2.4 B). However, these effects of LPA, AA and LPA 
plus AA on PGE2 generation were all highly sensitive to the Cox-2 enzyme inhibitor NS-
398 (Fig. 2.4 C). NS-398 did not affect LPA-induced Cox-2 protein expression (Fig. 2.4 
D). These results suggest that LPA activates both AA release and Cox-2 expression. The 
two processes cooperate to upregulate PGE2 levels in LPA-treated ovarian cancer cells.  
 
2.3.3 The LPA1, LPA2 and LPA5 receptors mediate LPA-induced Cox-2 expression  
To identify the LPA receptors responsible for Cox-2 induction, we assessed 
expression of LPA receptors in ovarian cancer cell lines by Northern blotting and RT-PCR. 
Caov-3 and OVCA-429 expressed mRNAs of the LPA1-3 receptors and the newly 
identified LPA5 receptor (Fig. 2.5). The RT-PCR product of LPA4 mRNA was not detected 
in Caov-3 cells and therefore was not further assessed for its role in Cox-2 induction. We 
utilized small interfering RNA (siRNA) to downregulate expression of each of the 
expressed LPA receptors in Caov-3 cells (Fig. 2.6 A). The expression of LPA1-3 and LPA5 
mRNAs was decreased by 60-80% as determined by RT-qPCR (Fig. 2.6 B). 
Downregulation of LPA1, LPA2 or LPA5 caused a significant suppression of LPA-induced 
Cox-2 expression (Fig. 2.6 A). In contrast, downregulation of LPA3 did not affect LPA-
dependent induction of Cox-2 (Fig. 2.6 A).  
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Fig. 2.4. Involvement of arachidonic acid (AA) and Cox-2 enzyme activity in PGE2 
production 
 AA release in Caov-3 cells treated with LPA (10 μM) or ATP (100 μM) for the indicated 
periods of time was quantified as described in Materials and Methods (A). The effect of 
exogenous AA (1 or 10 μM, 6 hr) on PGE2 production in Caov-3 cells was determined and 
compared with that of LPA (10 μM, 6 hr) (B). In (C), PGE2 production in Caov-3 cells 
induced by AA (10 μM, 6 hr), LPA (10 μM, 6 hr) and AA+LPA in the presence of the Cox-2 
inhibitor NS398 (50 μM) or vehicle was analyzed and compared. The results are mean ± SD 
of triplicates, representative of three independent experiments. The statistically significant 
differences were indicated with asterisks. 
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Fig. 2.5. Expression of LPA receptor subtypes of the Edg family in ovarian cancer cells. 
A, Northern blotting analysis of LPA receptor various cell lines was done labeled cDNA 
probes of LPA1, LPA2 and LPA3. GAPDH was used as loading control. B, the relative 
expression levels of LPA receptors in various normal and epithelial ovarian cancer cells were 
confirmed by RT-PCR. Other cells of epithelial origin were included for comparison. In C, 
RT-PCR was used to analyze the expression of novel LPA receptor, LPA5 in ovarian cancer 
cells. Lung cancer cells (HL-60) and gastric cancer cells (MLN-1) included for comparison. 
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Fig. 2.6. LPA stimulates Cox-2 expression through LPA1, LPA2 and LPA5 but not LPA3 
or PPARγ. 
A. Each of the LPA1-3 and LPA5 receptors in Caov-3 cells was downregulated by siRNA. 
Expression of LPA receptor mRNAs in the knockdown cells was determined by RT-qPCR 
and compared with that in control siRNA-treated cells which was defined as 100%. In B, the 
outcome of the LPA receptor knockdown was assessed by immunoblotting analysis of Cox-2 
expression induced by LPA (10 μM, 6 hr).  C, Caov-3 cells were stimulated with 1 or 5 μM 
LPA for 6 hr in the presence of indicated concentrations of the PPARγ antagonist GW9662. 
GW9662 was added 45 min before LPA. Similar results were obtained from three 
independent experiments  
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PPARγ can stimulate Cox-2 expression through activating the PPARγ binding sites 
located in the human Cox-2 gene promoter [202]. To address the possibility that LPA may 
stimulate Cox-2 expression via PPARγ, we treated Caov-3 cells with LPA in the presence 
of the PPARγ antagonist GW9662 [202]. GW9662 had little effect, if any, on LPA-
afforded Cox-2 expression (Fig. 2.6 C), indicating that LPA induces Cox-2 expression 
through a PPARγ-independent pathway.    
 
2.3.4 LPA induced Cox-2 gene expression does not depend on Gi, ERK or p38 
The LPA1 and LPA2 receptor subtypes couples to the Gi α subunit of the trimeric G 
proteins [204-206]. A number of biological actions of LPA are mediated by Gi-dependent 
signaling cascades including LPA-induced GROα expression as we described recently 
[192]. To investigate the potential role of Gi in LPA-regulated Cox-2 expression, we 
stimulated Caov-3 cells that were pre-treated with pertussis toxin (PTX), a specific 
inhibitor of Gi. LPA was fully capable of inducing Cox-2 expression in cells treated with 
PTX, indicating that LPA-induced Cox-2 expression is independent of Gi signaling 
cascades (Fig. 2.7). We also excluded the involvement of ERK or p38MAPK in the 
process, by using the pharmacological inhibitor of MEK (PD98059) and p38MAPK 
(SB203580) (data not shown). LPA stimulated a full magnitude of Cox-2 expression in the 
presence of various concentrations of these inhibitors (Fig. 2.7). These results suggest a 
novel pathway independent of Gi and MAPKs in LPA activation of the Cox-2 gene 
expression. 
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2.3.5 The effect of LPA involves both transcriptional activation and post-
transcriptional enhancement of Cox-2 mRNA stability  
Cox-2 is one of the immediate early response genes and its induction usually 
declines rapidly within 1-4 hours [207]. However, LPA-mediated Cox-2 protein expression 
lasted much longer in ovarian cancer cells and was detectable at high levels 12-18 hours 
after addition of LPA (Fig. 2.2). Consistent with this, Cox-2 mRNA levels reached the 
maximum at 6 hours and remained highly elevated at 12 hours (Fig. 2.8 A). The sustained 
induction of Cox-2 mRNA by LPA suggests that Cox-2 mRNA could be stabilized in 
LPA-treated cells. To examine this possibility, we compared the decay kinetics of Cox-2 
LPA     - +     - +    - +     - +        - +     - +    - +
MAPK-p
Cox-2
Cox-1
0          12.5         25         50                 0   15          30
PTX (ng/ml)                                 PD98059 (μM)
Fig. 2.7. Mechanism of LPA-induced Cox-2 gene expression is Gi and ERK independent 
A. Caov-3 cells were incubated with the indicated concentration of PTX before stimulation 
with 10μM LPA. Western blotting was performed to assess Cox-2 protein levels. Cox-1is 
included as a loading control. In B, the involvement of p38 MAPK was excluded, after 
western blot analysis from lysates of cells treated with PD98059 showed no inhibition of 
LPA-induced Cox-2 gene expression. 
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transcripts in Caov-3 cells treated with or without LPA. As shown in Fig. 2.8 B, Cox-2 
transcripts in control cells degraded quickly after actinomycin D was added to halt new 
RNA synthesis. In contrast, pretreatment with LPA led to significant stabilization of Cox-2 
mRNA as compared to untreated control cells (Fig. 2.8 B).  
 
Fig. 2.8. LPA induces both Cox-2 mRNA levels and posttranscriptional enhancement of 
Cox-2 mRNA stability. 
A. Caov-3 cells were stimulated with 10 μM LPA for the indicated periods of time. Total 
cellular RNA was extracted and analyzed by Northern blotting. The membrane was reprobed 
for 18S RNA to show equal loading among samples. In B, Caov-3 cells were treated for 6 hr 
with LPA (10 μM) or BSA (control) before addition of actinomycin D (Act D, 5 μg/ml). 
Total RNA was isolated from the cells at 0, 2, 4, and 6 hr after addition of Act D. The 
relative Cox-2 mRNA levels were determined by RT-qPCR and plotted as a function of 
hours postaddition of Act D. The values at 0 hr were defined as 100% with other time points 
presented as relative percentages.  
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To determine whether LPA induction of Cox-2 mRNA was initiated from 
transcriptional activation, we cloned an approximately 1 kb proximal fragment (-980 to 
+15) of the human Cox-2 gene promoter and evaluated its ability to drive transcription of 
the luciferase reporter in response to LPA. LPA stimulated 5-20 fold increases in luciferase 
activity in Caov-3 (Fig.  2.9 A). In addition, we compared the response of this reporter 
with that of a luciferase vector containing 7.2 kb 5’ flanking region (pGL2-Cox2-7.2kb-
Luc) [202]. Similar ranges of LPA-stimulated luciferase activity were obtained from each 
Fig. 2.9. Effect of LPA on Cox-2 expression involves transcriptional activation of Cox-2 
promoter 
Caov-3 cells transfected with pGL2-Cox2-1kb-Luc containing the –980-+15 fragment of the 
Cox-2 promoter were stimulated with LPA at the indicated concentrations for 6 hours and 
assayed for luciferase activity (A) LPA-induced luciferase activity from Caov-3 cells 
transfected with pGL2-Cox2-1kb-Luc (defined as 100%) was compared with the activity 
from the cells transfected with pGL2-Cox2-7.2bk-Luc (B). All numeric results were mean ± 
SD of triplicates, representative of three independent experiments. The statistically 
significant differences of the data were indicated with asterisks. 
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of the two plasmids, suggesting that essential LPA-regulatory elements are located within 
the 1 kb sequences of the Cox-2 promoter (Fig. 2.9 B).  
 
2.3.6 LPA induces transcriptional activation of Cox-2 via C/EBP  
To identify the transcription factors driving Cox-2 expression, we analyzed the 
Cox-2 gene promoter by deletion and mutation of the regulatory cis elements. Within the 1 
kb region that responded well to LPA, there are numerous transcription factor binding 
sites, including those for AP-1, NF-κB, and C/EBP (Fig. 2.10). Deletion of the unique AP-
1-like site at around -577 did not attenuate the response to LPA as determined by luciferase 
assays (Fig. 2.10). In agreement with this, ectopic expression of TAM67, a dominant 
negative form of c-Jun [208], did not inhibit LPA-induced Cox-2 (Fig. 2.11 A).  
Similarly, mutation of the two NF-κB consensus sites did not interfere with the 
responsiveness of the promoter to LPA (Fig. 2.10 A). Recent studies suggest that LPA and 
other GPCR agonists stimulate NF-κB activation through the CARMA3/Bcl10/Malt1 
signalosome, a process similar to antigen receptor-mediated NF-κB activation in 
lymphocytes [209, 210]. 
  71
 
Fig. 2.10. LPA induces transcriptional activation of Cox-2 through C/EBP 
independently of AP-1 or NF-κB. 
The unique AP-1-like, two NF-kB and two C/EBP binding sites were deleted or point 
mutated as detailed in Materials and Methods. Caov-3 cells transfected with the wild type or 
mutant constructs were treated with LPA for 6 hours and assayed for luciferase activity. 
tool.Data shown are representative of three independent experiments.  
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To confirm the mutagenesis results, we downregulated the expression of Bcl10 
with three individual siRNAs. Each significantly reduced Bcl10 expression. However, 
none of these siRNAs was able to prevent LPA-mediated Cox-2 expression (Fig. 2.11 B). 
In contrast, the Bcl10 siRNAs markedly inhibited LPA-stimulated IL-8 production (Fig. 
2.11 C), a response fully dependent on NF-κB activation as we described previously [9]. 
The results suggest that in sharp contrast to many other Cox-2 inducers, LPA stimulated 
Cox-2 expression independently of NF-κB although LPA potently induced NF-κB DNA-
binding and the transcriptional activity in these cells (Fig. 4.5 of Chapter 4).  
We next targeted the two C/EBP consensus motifs present in the 1 kb fragment of 
the Cox-2 promoter. Although mutation of the individual site only slightly decreased the 
promoter activity, simultaneous mutation of the two C/EBP sites resulted in almost 
complete loss of LPA-induced luciferarse activity (Fig. 2.10), suggesting that these 
C/EBP-binding sites are essential for the transcriptional activation of Cox-2 by LPA.  In 
further support of this, co-expression of LIP, a dominant negative, truncated form of 
C/EBP-β [139], inhibited LPA-induced luciferase activity by 60% in cells transfected with 
pGL-2-Cox2-1kb-Luc (Fig. 2.12 A). LIP also suppressed LPA-induced Cox-2 protein 
expression when transiently transfected and expressed in Caov-3 cells (Fig. 2.12 B). ChIP 
assay confirmed the recruitment of C/EBP-β to the Cox-2 gene promoter following LPA 
treatment (Fig. 2.12 C). Treated or untreated Caov-3 cell lysates were subjected to 
immunoprecipitation with anti-C/EBP-β and gel eletrophoretic analysis of precipitated 
DNA using Cox-2 promoter specific primers. As shown in Fig. 2.12 C, LPA induced a 
rapid localization of C/EBP-β to Cox-2 promoter sequences.  
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Fig. 2.11. Inhibition of AP-1 or NF-κB does not interfere with LPA-induced Cox-2 gene 
expression. 
In A, Caov-3 cells were transfected with pcDNA3-Tam67 or pcDNA3 using Amaxa 
nucleofector, stimulated for 6 hr with LPA (10 μM) and analyzed by immunoblotting for 
Cox-2. Control and Bcl10 siRNA-treated Caov-3 cells were stimulated for 6 hr with 10 mM 
LPA or vehicle. Cox-2 expression in cell lysates (B) and IL-8 concentrations (C) in culture 
supernatants were determined by immunoblotting and ELISA analysis, respectively. 
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C/EBP-β, a major isoform of the C/EBP family, was previously reported to be 
overexpressed in ovarian cancers [135]. To assess the effect of overexpression of C/EBP-
β on activity of the Cox-2 promoter, we transfected Caov-3 cells with pGL2-Cox2-1kb-
Luc along with the C/EBP-β LAP1, LAP2 or a control vector. Expression of the C/EBP-
β LAP1 or LAP2 was not sufficient to induce activation of luciferase activity from pGL2-
Cox2-1kb-Luc (data not shown). The observation suggests that LPA induced Cox-2 
expression requires C/EBP activation rather than changes in C/EBP-β protein levels. 
 
2.3.7 The mRNA-binding protein HuR associates with and stabilizes Cox-2 mRNA in 
LPA-treated cells  
There are several regulatory mechanisms to control mRNA stability under different 
physiological and pathophysiological conditions [211, 212]. One of such regulations 
involves the RNA-binding protein HuR that associates with AUUUA repeats present in the 
3’ UTR of mRNAs encoding cytokines and angiogenic factors [212, 213]. Two major Cox-
2 transcripts (2.8 kb and 4.6 kb) are derived from alternative polyadenylation of the Cox-2 
gene [212, 214]. 
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Fig. 2.12. C/EBP-β is crucial for transcriptional activation of Cox-2 expression by LPA 
Caov-3 cells transfected with pGL2-Cox2-1kb-Luc along with pcDNA3 or pCDNA3-LIP 
were treated for 6 hr with LPA (10 μM) and assayed for luciferase activity (A). In B, Caov-3 
cells were transfected with pcDNA3-LIP or pcDNA3 using Amaxa nucleofector, stimulated 
for 6 hr with LPA (10 μM) and analyzed by immunoblotting for Cox-2 and C/EBP-β. The 
values beneath each lane represent relative intensities (%) quantified by densitometry with 
Cox-2 induced by LPA in pcDNA3-transfected cells defined as 100% with other time 
pointspresented as relative percentages. (C) The presence of C/EBP-β near Cox-2 promoter 
was confirmed by ChIP assay (see Materials and Methods), by immunoprecipitation of 
control or 10μM LPA-treated Caov-3 cell lysate with anti-C/EBP-β or mouse IgG (N/A). 
Image of gel electrophoresis analysis of precipitated Cox-2 DNA fragment was quantified by 
NIH Image J 
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In ovarian cancer cells, LPA induced the 4.6 kb transcript which contains a long 3’-
UTR [212, 214]. The 2.8 kb transcript lacking the 3’-UTR was not induced at detectable 
levels by LPA (Fig. 2.8 A). Importantly, multiple AUUUA repeats are present within the 
3’-UTR of the 4.6 kb Cox-2 transcript [212, 215]. Moreover, HuR is highly expressed in 
primary ovarian cancers and ovarian cancer cell lines [216]. These observations prompted 
us to examine whether HuR participates in protection of Cox-2 mRNA stability, 
contributing to the persistent induction of Cox-2 observed in LPA-stimulated cells.  
We first examined whether HuR physically binds to Cox-2 mRNA in vitro. To this 
end, the 3’UTR of Cox-2 mRNA was synthesized and labeled with biotin by in vitro 
transcription. As demonstrated in Fig. 2.13 A, the Cox-2 3’-UTR was capable of binding 
with HuR protein from lysates of Caov-3 cells. Of note, incubation of 90 μg cellular 
protein with 1.5 μg Cox-2 3’-UTR brought down amounts of HuR similar to that present in 
30 μg cell lysates (Fig. 2.13 A). Therefore, approximately one third of the total HuR 
protein formed complex with the exogenous Cox-2 3’-UTR, demonstrating that HuR has a 
strong binding affinity for the Cox-2 3’-UTR at least in in vitro binding assays.  
To confirm that the HuR-Cox-2 mRNA association occurs within the cell, we 
immunoprecipitated HuR from Caov-3 cells treated with LPA or BSA for 6 hours. The 
immunocomplexes were then subjected to reverse transcription followed by PCR 
amplification of a 481bp fragment of Cox-2 cDNA. As shown in Fig. 2.13B, the fragment 
was detected in immunoprecipitates of the cells treated with LPA, but not present in that of 
control cells. It was also absent from immunoprecipitates of LPA-treated cells when a 
control antibody was used to replace the specific HuR antibody. HuR therefore indeed 
  77
formed complex with Cox-2 mRNA in LPA-treated cells. The lack of Cox-2 mRNA in the 
immunoprecipitates of control cells suggests that the interaction between HuR and Cox-2 
mRNA may not be constitutive. It could be regulated through activation of HuR protein or 
rely on LPA-dependent increases in Cox-2 mRNA abundance.  
To determine the functional significance of HuR binding to Cox-2 mRNA, we 
assessed the effect of downregulation of HuR on LPA-induced Cox-2 expression. 
Knockdown of HuR expression resulted in a significant decrease in LPA-induced Cox-2 as 
shown in Fig. 2.13 C. Stronger suppression of Cox-2 expression was observed in cells 
treated with LPA for 12 hours compared to the cells treated with LPA for 6 hours. The 
observation suggests that HuR-mediated stabilization of Cox-2 mRNA contributes more 
significantly to Cox-2 expression when transcriptional activation becomes less active after 
prolonged incubation with LPA. 
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Fig. 2.13. HuR binds to Cox-2 mRNA, contributing to the sustained induction of Cox-2 
by LPA. 
A.  In vitro transcribed, biotinylated 3’UTR of the Cox-2 mRNA (1. 5 μg) was incubated 
with cellular protein (90 μg) from Caov-3 cells treated with BSA or LPA (10 μM, 6 hr). 
Amounts of HuR pulled down by the Cox-2 3’UTR were analyzed by immunoblotting with 
an anti-HuR antibody. Cell lysates (30 μg) were included to serve as inputs. B. HuR was 
immunoprecipitated from Caov-3 cells treated for 6 hr with BSA (control) or LPA (10 μM). 
The mRNAs present in the HuR immunocomplex were extracted, reverse transcribed and 
amplified by PCR using Cox-2 specific primers as detailed in Materials and Methods. C. The 
control and HuR downregulated Caov-3 cells were stimulated for 6 hr (left) or 12 hr (right) 
with 10 μM LPA. Cox-2, Cox-1 and HuR levels in these cells were analyzed with 
immunoblotting. The values beneath each lane represent relative intensities (%) quantified by 
densitometry with Cox-2 induced by LPA in control siRNA-treated cells defined as 100%. 
Similar results were obtained from two independent assays. 
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2.4 Discussion 
In the present study, we demonstrated that LPA induces robust and sustained 
expression of Cox-2 in ovarian cancer cells through both transcriptional and post-
transcriptional mechanisms, mediated by the C/EBP transcription factor and the mRNA 
stability protein HuR, respectively. The identification of C/EBP as a primary transcription 
factor responsible for LPA-induced Cox-2 expression is somewhat surprising, as C/EBP 
has not been previously linked to any biological actions of LPA. Other transcription factors 
activated by LPA and commonly involved in inducible Cox-2 expression such as NF-κB 
and AP-1 are instead dispensable for LPA-induced Cox-2. Previous studies of GPCR 
regulation of Cox-2 in different cell systems have led to diverse mechanisms involving 
multiple transcription factors [217, 218]. A predominant and specific role of C/EBP in 
transcriptional activation of Cox-2 via GPCR signaling has not been previously described 
and likely represents a general mechanism regulating Cox-2 expression by LPA and other 
GPCR agonists in different cell types.  
Since C/EBP-β expression is elevated in primary ovarian cancers and in ovarian 
cancer cell lines [135], the isotype likely plays a major role in mediating transcriptional 
activation of Cox-2 in response to LPA. C/EBP-β has been shown to be a key transcription 
factor in regulation of Cox-2 expression by aspirin and salicylate [219]. Furthermore, 
expression of other isotypes of C/EBP such as C/EBP-α and C/EBP-δ is limited or 
undetectable in ovarian cancer cell lines (data not shown). We did not observe activation of 
the Cox-2 promoter by means of transfection of exogenous C/EBP-β, suggesting that 
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overexpression of C/EBP-β protein is insufficient to confer the transcriptional activation of 
Cox-2. The luciferase reporter analysis established that LPA treatment stimulates C/EBP 
transcriptional activity. There are multiple post-translational modifications associated with 
C/EBP activation including phosphorylation [220], acetylation [221] and sumoylation 
[201, 222]. Treatment with LPA resulted in prominent phosphorylation of C/EBP-β. It is 
not known whether LPA-dependent activation of C/EBP is also regulated by acetylation 
and sumoylation in addition to phosphorylation.  
LPA-induced Cox-2 gene expression is mediated by LPA1, LPA2 and LPA5 
receptors independent of LPA3 and LPA4. The LPA1 receptor is the most commonly 
expressed subtype present in both normal and cancerous tissues [62]. The LPA2 receptor 
subtype is abnormally overexpressed in ovarian cancers and other human malignancies 
[61, 62, 64]. It mediates LPA-dependent cytokine production in ovarian and breast cancer 
cells [9, 192]. Similarly, Hu et al. described that LPA2 expression correlates with the ability 
of LPA to induce VEGF expression in ovarian cancer cells [193]. The importance of LPA2 
in modulation of gene expression is further highlighted by the observation that transgenic 
expression of LPA2 driven by an ovary-selective promoter led to the production of higher 
levels of VEGF and uPA mRNA and proteins in ovaries of transgenic mice [223]. In 
addition to the role in modulation of gene expression, LPA2 may also regulate cell motility 
[224, 225]. Involvement of LPA5 in LPA-induced Cox-2 expression is an interesting 
observation since the biological functions of this new LPA receptor are totally unknown 
[40]. Requirement of LPA1, LPA2 and LPA5 in LPA induction of Cox-2 suggests that these 
LPA receptors could each contribute to the response to LPA. Alternatively, the effect of 
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LPA may depend on combined functions of these receptors. A recent study suggests that 
these LPA receptors can crosstalk to each other through forming heterodimers with 
signaling properties likely different from their homodimers [226]. In addition, the LPA3 
receptor does not seem to be a mediator of Cox-2 induction in ovarian cancer cells 
although this receptor is highly expressed in most ovarian cancer cell lines [62]. The result 
is inconsistent with the critical role of LPA3 in the uterine Cox-2 expression as suggested 
by studies of LPA3 knockout mice [199], indicating different LPA receptor subtypes are 
capable of mediating Cox-2 expression depending on the cellular context.  
The proximal region of the 3'-UTR of COX-2 mRNA contains highly conserved 
AU-rich elements that have potential to interact with multiple mRNA binding proteins 
including β-catenin, TIAR, AUF1, HuR, hnTIA-1 and hnRNP [211, 212, 215]. In the 
current study, we focused on the role of HuR, a member of the ELAV (embryonic lethal 
abnormal vision) family of mRNA-binding proteins [213]. HuR overexpression is 
associated with increased levels of Cox-2 protein in cancers of the colon, stomach, breast 
and ovary [135, 212, 227, 228]. However, few studies have provided direct evidence that 
HuR plays a causal role in Cox-2 overexpression in malignant cells. Our results indicate 
that HuR physically binds to the Cox-2 3’-UTR and protects Cox-2 mRNA stability. This 
protein-mRNA association contributes significantly to the sustained induction of Cox-2 by 
LPA. HuR thus provides a positive feedback to Cox-2 induction during physiological 
responses to LPA and probably other environmental stimuli.  
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CHAPTER 3 
MECHANISMS FOR ACTIVATION OF C/EBP-β BY LPA 
Part of the work presented in this chapter has been published FASEB J. 22:2639-2651 
(2008).  
 
3.0 Abstract 
We previously showed that LPA induced the expression of Cox-2, one of the 
enzymes that convert arachidonic acid to prostaglandins. Through site-directed 
mutagenesis and the ectopic expression of a dominant negative form C/EBP-β, we 
identified C/EBP-β as an essential transcription factor in the induction of Cox-2 gene 
expression by LPA. Here, we further examined the precise mechanisms underlying LPA-
induced activation of C/EBP-β. LPA induced a rapid and transient phosphorylation of 
C/EBP-β in ovarian cancer cells. Prolonged exposure to LPA stimulation caused an 
increase in C/EBP-β protein levels. Using electromobility shift assay, we show a sustained 
increase in DNA binding activity of C/EBP-β following LPA stimulation. Functionally, 
LPA induced multifold increase in C/EBP-β transcriptional activity in ovarian cancer cells 
transfected with a reporter construct of consensus C/EBP binding site. Furthermore, we 
report a novel mechanism integrating GPCR signals and a permissive activity from a 
receptor tyrosine kinase (RTK) in LPA-induced phosphorylation and activation of C/EBP-
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β. This role of RTK was not consistent with LPA activation of C/EBP-β through 
transactivation of RTK, as full activation of RTKs by their own agonists only weakly 
stimulated C/EBP-β activities. Interestingly, the Cox-2 promoter activity and gene 
expression were also dependent on RTK signaling, further substantiating the regulatory 
role of C/EBP-β in LPA-induced Cox-2 gene expression. These results together provide a 
picture of signaling cascades involved in LPA activation of C/EBP-β. 
 
 3.1 Introduction 
 C/EBP-β belongs to a widely expressed, highly conserved family of basic 
region-leucine zipper (bZIP) class of transcription factors that play essential role in many 
physiological and pathological processes such as cellular differentiation and inflammation 
[121, 126, 127]. Other members are C/EBP-α, C/EBP-γ, C/EBP-δ, C/EBP-ε, and C/EBP-ζ. 
The genes of most C/EBPs are intronless and exhibit a high degree of homology in the 
basic and leucine zipper regions [120, 121]. However, each C/EBP isoform may exhibit 
distinct functions. For instance, ablation of the C/EBP-α gene in mice led to neonatal 
lethality due to hypoglycemia and absence of stored liver glycogen [124, 129]. C/EBP-β-
null mice are, however, viable in spite of serious defects in hematopoiesis and the immune 
system [130, 131]. The C/EBP-β gene is expressed as three isoforms as a consequence of 
alternative initiation start sites within the C/EBP-β transcript:  liver-enriched activating 
proteins (LAP1—49kd and LAP2—45 kda) and liver-enriched inhibiting protein (LIP—20 
kda) [138, 139, 229]. The LAP isoforms function as activators of transcription while LIP, 
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which lacks the transactivation domain, is a dominant negative transcriptional repressor. 
The differential expression of these LAP and LIP is regulated by C/EBP-α  [140] and has 
been found to be critical in cell fate determination [141].  
Several studies have shown that C/EBP-β is important in mammalian reproduction 
including the development and differentiation of the mammary glands. C/EBP-β is also 
involved in ovarian follicular development and corpus leteum formation by enhancing the 
effects of lutenizing hormone (LH/hCG) [132-134]. Moreover, C/EBP-β null mice showed 
defective female reproduction [132]. C/EBP-β has been implicated in many cancer types 
and its expression highly correlates with aggressive behavior in ovarian cancer cells [135]. 
C/EBP binding sites are present in the promoters of cancer or metastasis-related genes such 
as interleukin 6 (IL-6), cyclooxygenase 2 (cox-2), urokinase plasminogen activator (uPA) 
and tumor necrosis factor alpha (TNF-α). In fact, C/EBP-β was identified in pioneer 
studies as a protein that binds the IL-1 response element on IL-6 promoter and hence, was 
originally named NF-IL6 [138, 230, 231]. We recently described C/EBP-β as an essential 
transcription factor for induction of the Cox-2 gene expression by LPA (Chapter 2 , [232] 
). The exact mechanism by which LPA induces activation of C/EBP-β has not been 
elucidated. 
Recent studies showed that many biological functions of GPCRs depend on EGFR. 
It is currently believed that ligands for GPCRs such as LPA activate cellular responses 
through transactivation of EGFR or other highly expressed RTK through the proteolytic 
release of EGFR ligands such as EGF or HB-EGF. The transactivation model is not 
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consistent with LPA stimulation of EGFR phosphorylation and activation. In addition, it is 
not known whether the crosstalk between GPCRs and EGFR involves activation of 
transcription factors such as C/EBP-β.  
Here, we provide evidence that LPA modulates the transcriptional activities of 
C/EBP-β in ovarian cancer cells by inducing its phosphorylation and DNA binding. LPA 
also induced expression of C/EBP-β at later time points which may contribute to the 
sustained induction of Cox-2. The effects of LPA on C/EBP-β phosphorylation, DNA-
binding and transcriptional activation required permissive signals from EGFR or an 
alternate RTK. The dependence of LPA actions on RTK also applies to other C/EBP-β 
target genes including IL-6 and uPA in addition to Cox-2 underscoring a general role of 
RTK in GPCR activation of C/EBP-β and C/EBP-β-target genes. 
 
3.2 Materials and Methods 
 
Materials 1-Oleoly (18:1) LPA and sphingosine 1 phosphate (S1P) were obtained from 
Avanti Polar Lipids, Inc. (Alabaster, AL). Prior to use, these phospholipids were dissolved 
in PBS containing 0.5% fatty acid-free bovine serum albumin (BSA). BSA, Fugene 6 and 
protease inhibitor cocktail tablets were purchased from Roche (Indianapolis, IN). [Plasmid 
DNA was purified using the endo-free purification kit from Qiagen (Valencia, CA). 
Luciferase assay reagents were obtained from Promega (Madison, WI). All 
oligonucleotides and primers were synthesized by Operon Biotechnologies, Inc 
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(Huntsville, AL). QuikChange XL site directed mutageneis kit were purchased from 
Stratagene (La Jolla, CA). Anti-phospho CEBPβ and anti-tubulin α/β antibodies were 
obtained from Cell Signaling (Danvers, MA). Insulin and cell culture medium were 
obtained from Invitrogen Inc. (Carlsbad, CA). Bovine fetal serum was from Biomeda 
(Foster City, CA). Insulin-like growth factor I (IGF-I) was from Upstate Biotechnology 
(Lake Placid, NY). Hepatocyte growth factor (HGF) and Quantikine IL-6 ELISA kit were 
from R & D systems (Minneapolis, MN). Anti-uPA monoclonal antibody #394 was 
obtained from American Diagnostica (Stamford, CT). Epidermal growth factor (EGF), 
AG1478 and anti-β-actin monoclonal antibody were obtained from Sigma (St. Louis, MO). 
 
Plasmids Construction Transcription factor binding sites were identified using 
TFSEARCH. The construction of Cox-2 promoter plasmid, pGL2-Cox-2-1kb-luc, has been 
described in Materials and Method section of Chapter 2 of this dissertation. The C/EBP 
responsive luciferase vector (pGL2-5xCEBP-TKLuc) was generated by cloning five 
repeats of the C/EBP consensus sequence (TTGCGCAATCT) into the Nhe1 and Hind III 
sites in front of the herpes simplex virus thymidine kinase (TK) gene promoter (-35-+50) 
in the pGL2-TK-Luc vector. The C/EBP-β, liver-enriched transcriptional activator protein 
1 (LAP1) and LAP2 expression vectors were kindly provided by Dr. L. Sealy (Vanderbilt 
University School of Medicine) [139, 201]. The expression of C/EBP-β from these vectors 
in transfected cells was confirmed by immunoblotting. The dominant negative form of 
C/EBP-β, LIP (liver-enriched inhibitory protein) [139] was cloned into pcDNA3.1 by RT-
PCR amplification of a 444 bp cDNA fragment of C/EBP-β from Caov-3 cells. The 
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structure of pcDNA3-LIP was confirmed by automatic sequencing and immunoblotting 
analysis of expression of the short, truncated form of C/EBPβ (21 kD) [139]in transfected 
cells.  
 
Cell Culture The sources of ovarian cancer cell lines used in the study were described 
previously [9, 192]. These cells were cultured in RPMI medium supplemented with 10% 
FBS, 100 units/ml penicillin and 100 μg/ml streptomycin. All cell lines were frozen at 
early passages and used for less than 10 weeks in continuous culture.  
 
Western Blot Cells were lysed in SDS sample buffer or in ice-cold X-100 lysis buffer [1% 
Triton X-100, 50 mM HEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 
10% glycerol, 100 mM NaF, 10 mM Na PPi, and protease inhibitor cocktail]. Total cellular 
proteins were resolved by SDSPAGE, transferred to Immun-Blot membrane 
[poly(vinylidene difluoride)] (BIO-RAD, Hercules, CA), and immunoblotted with 
antibodies following the protocols of manufacturers. Immunocomplexes were visualized 
with an enhanced chemiluminescence detection kit from Amersham (Piscataway, NJ) 
using the horseradish peroxidase–conjugated secondary antibodies (Cell Signaling, 
Danvers, MA). 
 
Transient transfection  and luciferase assays Ovarian cancer cell lines were seeded in 6-
well plates and grown to 30-40 % confluence before transfection with the luciferase 
vectors using Fugene 6 (Roche) or TransIT-TKO (Mirus Bio Corp., Madison, WI) 
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according to the instructions of the manufacturers. About 48 hours after transfection, the 
cells were starved for 24-36 hours before stimulation with LPA or vehicle for 6 hours. Cell 
extracts were prepared and assayed for luciferase activity using the luciferase assay kit 
from Promega. The luciferase activity was normalized on the basis of the activity of 
cotransfected β-galactosidase reporter driven by the cytomegalovirus promoter (pCMVβ-
gal).  
 
Nuclear and Cytoplasmic Extract Preparation – LPA-stimulated or control cells were 
washing twice with cold PBS, harvested by scraping with a rubber policeman and 
centrifuged at 1000 rpm for 3 min. Cell pellets were resuspended in a hypotonic lysis 
buffer [10 mM Tris-HCl (pH 7.4), 10 mM KCl, 3 mM MgCl2, 0.5% NP-40], incubated for 
15 min on ice, and centrifuged at 3000 rpm. The supernatants containing cytosolic proteins 
were collected and stored at -80 oC immediately. The nuclei pellets were washed once with 
the hypotonic lysis buffer, resuspended in hypertonic nuclear lysis buffer (50 mM Tris-
HCl(pH 8.3), 0.4M NaCl, 40% glycerol, 5 mM MgCl2 and 0.1 mM EDTA) and further 
incubated for 10 mins before centrifugation at 13,000 rpm. The supernatant was collected 
and quick-frozen in liquid nitrogen before storage in -80 oC. Protein concentration was 
determined with Pierce BCA kit. 
 
Non-radioactive electromobility shift assay (EMSA)- Biotin-labeled self complementary 
C/EBP consensus oligonucleotides 5’ [biotin] GGTGCAGATTGCGCAATCTGCA 3’ was 
synthesized by Operon Biotechnologies and annealed in 20 mM Tris (pH 7.4), 1 mM 
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dithiothreitol, 50 mM NaCl and 10 mM MgCl2. For the gel shift assay, binding reaction 
was performed by incubating 4 μg of nuclear protein in gel shift buffer (10 mM HEPES 
(pH 7.8), 10% glycerol, 1 mM EDTA, 25 mM MgCl2, 50 mM KCl,  1 µg of poly(dI.dC), 3 
µg BSA and protease inhibitors) in a final volume of 20 µL for 10 mins at 25oC. The 
biotin-labeled and unlabeled (cold) oligonucleotides were added to the reaction mixture, 
incubated for an additional 15 mins at 25oC. In supershift experiments, nuclear extracts 
were incubated for 15 min at room temperature with 1 µg of anti-CEBP-β monoclonal 
antibody (Santa Cruz Biotech) prior to gel shift reaction. Complexes were separated by 
electrophoresis on 5% non-denaturing polyacrylamide (PAGE) gel, transferred to a nylon 
membrane (Amersham Hy-bond XL)  and crosslinked using UV Stratalinker 2400 
(Stratagene). The signals were visualized by using Phototope-Star biotin detection kit 
(NEB), according to the manufacturer’s protocol. 
 
ChIP assay- Cells were fixed by cross-linking the chromatin with 1% formaldehyde for 5 
min, cells, scraped with a rubber policeman and collected by centrifugation. The cells were 
sonicated six times, 15 seconds each with 1-min intervals under ice by using a Sonic 
Dismembrator (Fisher Scientific). The average fragment size was 600 bp under these 
conditions. An equal amount of chromatin was incubated with at least 5 µg of either 
C/EBP-β-specific immunoglobulin G (IgG) or normal mouse IgG (Santa Cruz Biotech) at 4 
°C overnight. IP products were collected after incubation with protein G-coated sepharose 
beads (Amersham). The beads were washed, protein-DNA cross-links were reversed, and 
DNA was purified by Qiagen PCR purification columns according to manufacturer’s 
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instructions. Purified DNA from the input and IP samples were subjected to real-time 
quantitative PCR with uPA promoter specific primers. 
 
ELISA Assay- An enzyme-linked immunosorbent assay (ELISA) was used for the 
quantification of IL-6. Briefly, culture supernatants of Caov-3 treated without or with LPA 
or other ligands were collected and analyzed for IL-6 using the Quantikine IL-6 ELISA kits 
(R&D Systems) according the manufacturer’s instruction. Colorimetric reactions were read 
on a EL800 microplate reader (Bio-TEK Instruments, Winooski,VT). The concentrations 
of IL-6 in samples were calculated by comparing with those of standards provided with the 
ELISA kits. 
 
Stable expression of C/EBP-β LIP by retrovirus – The human LIP cDNA was excised 
from pcDNA3-LIP using HindIII and EcoRI and cloned into a moloney murine leukemia 
retrovirus vector, S-001AB (LZRS-EGFP)( a gift from Dr. J. Chun, the Scripps Research 
Institute, La Jolla, CA). The complete insert and flanking regions of the final retrovirus 
vector were confirmed by automatic sequencing. The LZRS-EGFP-LIP and control vector 
were transfected into the PZ67 packaging cell line with lipofectamine 2000 as previously 
described [9]. Virus stocks were harvested 72 hrs post-transfection by centrifugation of the 
supernatants at 2100 rpm for 10 min and stored in -80 °C. Skov-3 cells grown in 6-well 
dishes were infected with 1.4 ml virus to cells in the presence of 7.5 μg/ml polybrene 
(Sigma-Aldrich) and incubated at 37 oC overnight. The infection medium was then 
replaced with growth medium. Cells were split into 10 cm dishes after 48 hours. Viral-
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transduced GFP-positive cell were sorted out by flow cytometry at the VCU flow 
cytometry core facilities. 
Table 3.1 Plasmids and Primers 
Plasmid Wildtype or Mutation primers 
pGL2-Cox-1kb-Luc 5’-TTTAGCGTCCCTGCAAATTCTGGC-3’(SENSE)  
5’-CGCTCACTGCAAGTCGTATGACAA-3’ (ANTISENSE) 
pGL2-IL-6-Luc 5’- GAGCTCAAGGATCCTCCTGCAAGAGA -3’(SENSE)  
5’- TAGAGCTTCTCTTTCGTTCCCGGTGG -3’ (ANTISENSE) 
pGL2-IL-6-mut-Luc 5’- GGACGTCACAGTCTACTCTCTTAATAAGGTTTCC -3’(SENSE)  
5’- GGAAACCTTATTAAGAGAGTAGACTGTGACGTCC -3’ (ANTISENSE) 
pGL2-uPA-Luc 5’- CGGATCACAAGGTCAGGAAGATCGAG -3’(SENSE)  
5’- TCTCCGACTGTGCTGCGA C 3’ (ANTISENSE) 
pGL2-uPA-mut-Luc 5’- GAGGCAGTCTTAGGCGGGTTGGGGCCCAGCG -3’(SENSE)  
5’- CGCTGGGCCCCAACCCGCCTAAGACTGCCTC -3’ (ANTISENSE 
pGL2-5xCEBP-TK-
Luc 
5’CTAGCATCTAAGTTTGCGCAATCTTTGCGCAATCTTTGCGCAATCTTTGC
GCAATCTTTGCGCAA -3’(SENSE)  
5’AGCTTTTGCGCAAAGATTGCGCAAAGATTGCGCAAAGATTGCGCAAAGA
TTGCGCAAACTTAGAT 3’ (ANTISENSE) 
pcDNA3-LIP 5’-GGAATCAAGCTTGGCGCACATGGCGGCG-3’ (SENSE)  
5’-GCAATACTCGAGCGCTAGCAGTGGCCGGAGG-3’ (ANTISENSE). 
 
 
3.3 Results 
3.3.1 LPA induces phosphorylation and protein expression of C/EBP-β 
We previously established the necessity for C/EBP binding and transcriptional 
activity in LPA-induced gene expression using Cox-2 as a model [232]. A major 
biochemical process associated with transcriptional activation of C/EBP-β is 
phosphorylation. We examined whether LPA triggers activation of C/EBP-β by 
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modulating the phosphorylation status of the protein. By western blot analysis of total cell 
extract from Caov-3 cells, we showed that stimulation with LPA caused a rapid 
phosphorylation of C/EBP-β (Fig. 3.1 A). The signal decreased after 30 mins incubation 
with LPA. However, levels of phosphorylated C/EBP-β remained substantially elevated 
above background hours after exposure to LPA. In some cell models, phosphorylation has 
been shown to be prerequisite for nuclear transportation of C/EBP-β [142]. As such, we 
assessed the influence of LPA stimulation on nuclear-cytoplasmic partitioning of C/EBP-β. 
As shown in Fig. 3.1 B and Fig. 3.1 C, C/EBP-β was exclusively resident in the nucleus in 
both untreated and treated Caov-3 and Skov-3 cells. Further, LPA did not induce 
cytoplasmic translocation of C/EBP-β, an event that has been shown to result in 
suppression of C/EBP-β target genes [233, 234]. However, we observed significant 
increase in expression levels of C/EBP-β after prolonged stimulation of ovarian cancer 
cells with LPA (Fig. 3.1 B and C). This is consistent with the fact that C/EBP-β promoter 
possesses binding sites for C/EBP [235, 236]. Thus, C/EBP-β may be auto-induced in 
LPA-treated cells. 
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Fig. 3.1 LPA induces phosphorylation and expression of C/EBP-β in ovarian cancer 
cells. 
A. Caov-3 cells were stimulated with 10 μM LPA for the indicated periods of time. Total cell 
lysates were analyzed by western blotting for phosphorylated C/EBP-β. In B and C, C/EBP-
β protein levels were analyzed by western blotting in cellular fractions of serum-starved 
Caov-3 and Skov-3 cells respectively, following treatment with 10 μM of LPA for indicated 
periods of time. β-actin was used as loading control for cytoplasmic protein and lamin a/c as 
control for nuclear proteins.  
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C 
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C/EBP-β-p
C/EBP-β
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Pretreatment of Caov-3 cells with Cycloheximide, an inhibitor of protein synthesis, 
completely abrogated LPA-induced C/EBP-β expression (Fig. 3.2). This confirmed that the 
increase in C/EBP-β at later time points was indeed a consequence of new protein 
synthesis. It is likely that newly synthesized C/EBP- β may be further activated in the 
presence of LPA. The ability of LPA to elevate C/EBP-β in the nucleus may be part of a 
mechanism to ensure the long term effects of LPA on gene expression. 
 
 
 
 
0h  2h  4h  0h 2h 4h  0h  2h  4h  0h   2h   4h    LPA
Cytosolic Extract Nuclear Extract
C/EBP-β
Tubulin
Cox-2
Lamin A/C
Cycloheximide- +              - +
Fig. 3.2. Induction of C/EBP-β expression by LPA is a consequence of new protein 
synthesis 
Caov-3 cells Caov-3 cells were stimulated with 10 μM LPA for 6 hr in the presence of 10 
μg/ml cycloheximide, protein synthesis inhibitor. Cycloheximide was added 45 min before 
LPA stimulation. Cellular fractions were analyzed by Western blotting. Similar results were 
obtained from three independent experiments.  
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3.3.2 LPA induces C/EBP-β DNA-binding and transcriptional activities 
 C/EBP-β contains intramolecular inhibitory elements that hinder its DNA binding 
site [237]. Phosphorylation of C/EBP-β has been shown to increase its DNA binding 
activity in vitro [220]. To determine whether C/EBP-β phosphorylation induced by LPA 
result in enhancement in C/EBP-β DNA binding activity, we performed electromobility 
shift assay. The binding of C/EBP to consensus oligonucleotides was increased following 
LPA stimulation (Fig 3.3 A) and bound complexes were supershifted in the presence of 
anti-C/EBP-β. The binding depended on C/EBP-β phosphorylation as it was blocked by 
pretreatment of nuclear extract with potato alkaline phosphatase (PAP) to remove 
phosphate groups (Fig 3.3 B). Further, C/EBP-DNA complexes significantly increased at 
later time points when more C/EBP-β was present (Fig. 3.3 A and B).   
Next, we constructed a C/EBP-responsive luciferase plasmid (pGL2-5xCEBP-TK-
Luc), in which five copies of the C/EBP consensus sequence were linked to the basic TK 
promoter. As shown by Fig. 3.3 C, LPA stimulated 5-10 fold increase in luciferase activity 
in pGL2-5xCEBP-TK-Luc-transfected ovarian cancer cells but not in the cells transfected 
with the backbone vector lacking the C/EBP responsive sites (pGL2-TK-Luc). Taken 
together, these results indicate that LPA induces C/EBP-β DNA-binding and 
transcriptional activities. 
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Fig. 3.3. LPA activates binding and transcriptional activities of C/EBP-β . 
A, Nuclear extracts obtained from Caov-3 cells stimulated with 10 μM LPA for the indicated 
periods of time were subjected to gel shift assay (EMSA) (see Materials and Methods). 
Supershift experiments were performed on 2h LPA-treated nuclear extracts using 2 and 5 μg 
anti-C/EBP-β mouse monoclonal antibody. For dephosphorylation of nuclear extracts, 1 unit 
of potato alkaline phosphatase (PAP) was added for 15 min prior to binding reaction (B). In 
C, Caov-3 cells were transfected with a luciferase construct of a 5 copies of C/EBP binding 
sites upstream of a TK promoter. Cells were treated with 10 μM LPA for 6 hours and 
analyzed for luciferase activity. 
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3.3.3 LPA stimulates activation of C/EBP-β through a regulatory mechanism 
integrating GPCR signal(s) and a permissive activity of RTK 
In comparison with LPA, agonists of RTKs including EGF, HGF and IGF only 
weakly induced the expression of LPA-target genes such as Cox-2 (Fig. 2.2 D). Similarly, 
C/EBP-β seemed to be preferentially activated by LPA because RTK agonists, EGF, IGF 
Fig. 3. 4 RTK agonists weakly induce C/EBP-β activity in ovarian cancer cells. 
 A, Serum-starved Caov-3 cells were treated with LPA (10 μM) or HGF (25 ng/ml) for the 
indicated time and phosphorylated C/EBP-β was examined by Western blotting analysis. 
Serum-starved Caov-3 cells transfected with construct of a 5 copies of C/EBP consensus 
binding site were treated with LPA (10 μM), EGF (50 ng/ml), HGF (25 ng/ml) or IGF (25 
ng/ml) and assayed for luciferase activity (B). Data shown are representative of three 
independent experiments. 
B 
A 
C/EBP-β-p
C/EBP−β
0' 10' 30' 1h    2h   10'   30'  1h    2h   LPA
HGF LPA
0
20
40
60
80
L
PA
H
G
F
E
G
F
IG
F
B
SA
R
el
at
iv
e 
L
uc
ife
ra
se
U
ni
t (
R
L
U
) pGL2-5xCEBP-TK-Luc
L
PA
H
G
F
E
G
F
IG
F
B
SA
R
el
at
iv
e 
L
uc
ife
ra
se
U
ni
t (
R
L
U
)
  98
and HGF, were weak stimuli of C/EBP-β phosphorylation (Fig. 3.4 A) and transcriptional 
activity (Fig. 3.4 B). However, pretreatment of Caov-3 cells with a specific inhibitor of 
EGFR kinase activity, AG1478, resulted in a profound decrease in LPA-induced 
phosphorylation of C/EBP-β (Fig. 3.5 A). AG1478 attenuated the LPA-induced increase in 
C/EBP-β protein levels (Fig. 3.5 B). In addition, LPA-induced binding of C/EBP to its 
consensus oligonucleotide (Fig. 3.5 C) and C/EBP mediated transactivation, as measured 
by the C/EBP-responsive luciferase vector were significantly inhibited by AG1478 (Fig. 
3.5 D). Therefore, LPA-induced C/EBP-β phosphorylation, DNA binding and functional 
activation were invariably sensitive to EGFR inhibition suggesting that EGFR activity, 
albeit insufficient on its own to trigger strong C/EBP-β activation, was required for LPA 
GPCR signaling to C/EBP-β.  
We observed that compared to EGF, LPA only weakly induced activation of 
EGFR, as assessed by phosphorylation at Y-1068 (Fig. 3.5 E), ruling out the possibility 
that LPA activation of C/EBP-β was through transactivation of EGFR. To further explore 
this novel mode of crosstalk between the two receptor types, we examined whether the 
requirement of EGFR in the process could be relieved by activation of another RTK, such 
as c-Met. Treatment of Caov-3 cells with HGF alone only slightly activated C/EBP-β 
phosphorylation (Fig. 3.4 A) and C/EBP transcriptional activity (Fig. 3.4 B). However, 
when EGFR was inhibited by AG1478, LPA was fully capable of stimulating C/EBP-β 
phosphorylation (Fig. 3.5 A) and transcriptional activity (Fig. 3.5 D) if cells were co-
stimulated with HGF to activate c-Met. Taken together, these results demonstrate that  
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Fig. 3.5. EGFR inhibitor blocks LPA-induced activation of C/EBP-β 
Serum-starved Caov-3 cells were treated with LPA (10 μM) and/or AG1478 (1 μM) for the 
indicated time and phosphorylated (A) or total C/EBP-β (B) was examined by Western 
blotting analysis. Co-stimulation with HGF (25 ng/ml) in the presence of AG1478 restored 
LPA-induced phosphorylation of C/EBP-β (A). C, nuclear extracts from LPA-treated or 
untreated Caov-3 cells were analyzed by gel shift assay using biotin-labeled consensus 
C/EBP oligonucleotides (see Materials and Methods). Band intensities were quantified with 
NIH Image J tool. In D, Caov-3 cells transfected with a luciferase construct of a 5 copies of 
C/EBP binding sites upstream of a TK promoter. Serum-starved transfected cells were then 
pretreated AG1478, stimulated with LPA and/or HGF for 6 hours and examined for 
luciferase activity. Cell lysates of Caov-3 cells stimulated indicated agonists for 30’ were 
analyzed by western blotting for tyrosine 1068 phosphorylation of EGFR (E). Results are 
representative of three independent experiments.
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RTK, not necessarily EGFR, provides an obligatory activity that acts in concert with LPA 
GPCR signaling to activate C/EBP-β.  
 
3.3.4 RTK-dependent activation of C/EBP-β mediates induction of Cox-2 and other 
LPA-target genes  
Our observation that LPA induced the expression of Cox-2 in a C/EBP-β-
dependent manner led us to ask whether the requirement of RTK for C/EBP-β activation 
also applied to LPA-induced Cox-2 gene expression. Compared to LPA, agonists of RTK, 
including EGF, HGF and IGF only weakly induced Cox-2 expression in Caov-3 cells as 
shown in Fig. 3.6 A. Similarly, these RTK agonists were weak stimuli of C/EBP-
β transcriptional activity as indicated by luciferase assays with the C/EBP-responsive 
construct pGL2-5x-CEBP-TK-luc (Fig. 3.4 B). Thus, C/EBP-β seems to be rate-limiting 
regulator of Cox-2, preferentially activated by GPCRs rather than RTKs. In further support 
of the role of C/EBP-β in the transcriptional activation of Cox-2, HGF efficiently reversed 
the inhibitory effect of AG1478 not only on C/EBP-β activation (Fig. 3.5 A and D) but 
also on LPA-induced Cox-2 (Fig. 3.6 B). 
In addition to Cox-2, a subset of LPA target genes including IL-6 and uPA bear 
binding sites for C/EBP in their promoters (Fig. 1.2 of Chapter 1). IL-6 is a pleiotropic 
cytokine and a prominent mediator of inflammation. ELISA analyses of conditioned 
medium from Caov-3 cells treated with LPA showed a robust increase in IL-6 production 
(Fig. 3.6 C). The ability of LPA to induce the expression of IL-6 in many cell models may 
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explain why high concentrations of IL-6 are present in the ascites of ovarian cancer 
patients [238, 239]. In addition, IL-6 levels in ovarian cancer correlate with poor prognosis 
[240].  
It has been reported that C/EBP-β activates IL-6 promoter in response to IL-1, 
bacterial LPS and many other stimuli [241, 242]. To assess the contribution of C/EBP-β to 
LPA-induced IL-6 expression, we constructed a luciferase reporter carrying 1.2 kb of 
wildtype IL-6 promoter. Disruption C/EBP binding site by point mutation dramactically 
decreased the IL-6 promoter activity induced by LPA by 60% loss in promoter response to 
LPA as measured by luciferase assay (Fig 3.6 D). Co-transfection of Caov-3 cells with 
inhibitory C/EBP-β isoform, LIP, also attenuated the IL-6 promoter activation by LPA 
(Fig. 3.6 E). Stable expression of LIP in Skov-3 cells (Fig. 3.6 F, lower right) (see 
Materials and Methods) caused a modest reduction of LPA-induced IL-6 production (Fig. 
3.6 F), suggesting that stably-transfected Skov-3-LIP cells may have activated some 
mechanisms to suppress the effects of enhanced LIP/LAP ratio, such that the impact of 
inhibiting transcriptional activities of C/EBP-β on LPA-induced IL-6 gene expression 
becomes not as dramatic as in transient experiments. However, AG1478 inhibited LPA-
induced IL-6 promoter response and IL-6 production (Fig. 3.6 G). Similarly, co-
stimulation with HGF restored the ability of LPA-stimulated Caov-3 cells to generate IL-6. 
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Fig. 3.6. RTK-dependent activation of C/EBP-β mediates induction of Cox-2 and IL-6. 
A. Serum-starved Caov-3 cells transfected with Cox-2 promoter construct were treated with 
LPA (10 μM), EGF (50 ng/ml), HGF (25 ng/ml) or IGF (25 ng/ml) and assayed for luciferase 
activity (B) Cox-2 protein levels in Caov-3 cells pretreated AG1478 and stimulated with 
LPA and/or HGF, were examined by Western blotting analysis. In C, cultured supernatant of 
Caov-3 cells treated with or without LPA for 18hrs were assayed for IL-6 by ELISA. D,  
Caov-3 cells transfected with wildtype or C/EBP mutated IL-6 promoter were treated with 
LPA for 6 hours before luciferase assay.  
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Fig. 3.6 (cont’d). RTK-dependent activation of C/EBP-β mediates induction of Cox-2 
and IL-6. 
E, Caov-3 cells cotransfected with IL-6 promoter construct and pcDNA3-LIP were treated 
with LPA (10 μM) for 6 hours and assayed for luciferase activity. In F, concentrations of IL-
6 in cultured supernatant of Skov-3 cells stably transfected with retrovirus expression 
plasmid of LIP or control vector were measured by ELISA (top right). Expression of LIP 
was confirmed by Western blotting analysis (bottom right). G, cultured supernatants of 
Caov-3 cells pretreated with or without AG1478 and stimulated with LPA, EGF or HGF for 
18 hours were assayed for IL-6 concentrations by ELISA. Data shown are representative of 
three independent experiments. 
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Finally, consistent with previous studies, LPA induced the activation of uPA, an 
important component of tumor cell invasion and metastasis (Fig. 3.7 A). We evaluated the 
involvement of C/EBP-β in LPA-induced activation of uPA gene expression. By utilizing 
ChIP assay (see Materials and Methods), we found an increased presence of C/EBP-β at 
the uPA promoter after 2 hours following LPA stimulation (Fig. 3.7 B). Compared to 
wildtype construct, mutation of the proximal C/EBP binding site on uPA promoter 
(uPAmut-luc) resulted in a partial yet significant decrease in LPA-induced promoter 
activity (Fig. 3.7 C). Co-transfection of LIP in Caov-3 cells also markedly decreased uPA 
promoter activation by LPA (Fig. 3.7 D). In agreement with activation of C/EBP-β, 
AG1478 completely abrogated LPA-induced uPA activation (Fig. 3.7 E). These results 
established that RTK-dependent activation of C/EBP-β reflects a general signaling 
mechanism to regulate expression of LPA-target genes Cox-2, IL-6 and uPA.  
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Fig. 3.7. LPA activation of uPA involves C/EBP-β and requires EGFR kinase activity. 
A, Serum-starved Caov-3 cells lysate were stimulated with 10 μM LPA for 18hrs and 
analyzed by Western blotting under non-reducing conditions for activated uPA. B, Caov-3 
cells were treated with LPA for the indicated period of time and then subjected to ChIP 
assay (see Materials and Methods). Immunoprecipitation was done using anti-C/EBP-β 
monoclonal antibody or no antibody (N/A). Purified DNA from inputs (crude chromatin) 
and immunoprecipitates were analyzed by qPCR using uPA promoter-specific primers. 
Results of uPA DNA average values in samples were normalized to corresponding input 
values. PCR and agarose gel electrophoresis were used to analyze DNA of crude inputs 
(bottom). 
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Fig. 3.7 (cont’d). LPA activation of uPA involves C/EBP-β and requires EGFR kinase 
activity. 
Serum-starved Caov-3 cells transfected with wildtype or C/EBP mutated uPA promoter (C), 
and in (D) uPA promoter construct and pcDNA3 or pcDNA3-LIP were treated with LPA for 
6 hours and analyzed for luciferase activity. Data shown are representative of three 
independent experiments. E, serum-starved Caov-3 cells pretreated with or without AG1478 
and stimulated with LPA were analyzed by Western blotting under non-reducing conditions 
for activated uPA . Data shown are representative of three independent experiments. 
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3.4 Discussion  
In this chapter, we explored the signaling mechanisms by which LPA stimulates 
activation of C/EBP-β, a key transcription factor in LPA induction of Cox-2. Our results 
indicated that LPA induced phosphorylation of C/EBP-β, which correlated with increase in 
C/EBP-β DNA binding activity. By analyzing different cellular fractions, we found that 
C/EBP-β was essentially localized to the nuclei in ovarian cancer cells. A very minute 
amount was present in the cytoplasmic fraction. LPA did not cause any translocation of 
C/EBP-β between cytosol and nucleus. At later hours, there was net increase in total 
C/EBP-β protein levels in LPA-treasted cells, probably reflecting auto-induction by 
C/EBP-β itself as the C/EBP-β promoter contains C/EBP consensus sequences. The 
increase in C/EBP-β protein levels could contribute to sustained effects of LPA on 
expression of Cox-2 and other LPA-target genes. 
In pursuit of the molecular mechanism linking the LPA receptors to C/EBP-β 
activation, we observed that LPA-induced C/EBP activation involves an obligatory activity 
from EGFR. Fig. 3.8 is a simplified representation of this obligatory role of EGFR in LPA 
GPCRs signaling. Transactivation of EGFR has been proposed as a mechanism to mediate 
many biological actions of LPA in numerous studies [181, 243]. In contrast, the possibility 
for involvement of a parallel RTK signal in biological responses to LPA or other GPCR 
agonists has been rarely studied [189]. In our experiments, EGF and other RTK agonists 
only weakly stimulated C/EBP-β activity compared to LPA, allowing us to distinguish the 
input of GPCR from that of RTK in these cells.  
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Based on the differential abilities of LPA and EGF to activate C/EBP-β, it is hard 
to imagine that transactivation of EGFR could trigger robust activation of C/EBP-β and 
Cox-2 expression in LPA-stimulated cells. It is more likely that optimal activation of 
C/EBP-β relies on combinatorial signaling components from LPA GPCR(s) and EGFR. 
The EGFR signal may feed in at some point downstream of GPCRs. Furthermore, our 
Fig. 3.8. Hypothetical model of LPA GPCR-RTK crosstalk in activation of 
transcription factors and gene expression. 
Basal activity of EGFR synergizes with signals from LPA GPCR to mediate transcription 
factor activation. Inhibition of EGFR kinase activity with pharmacological inhibitor AG1478 
attenuates LPA-induced activation of gene expression. Activation of another RTK, c-Met by 
costimulation with HGF in the presence of AG1478 rescues LPA signals to transcription 
factors. 
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results indicate that activities of other RTKs, not necessarily EGFR, could cooperate with 
the LPA GPCR(s) in regulation of C/EBP activity. EGFR is usually recognized to serve 
such a role probably because it is more universally expressed and exhibits higher activity 
than other RTKs, particularly in cancer cells [244]. The high EGFR activity present in 
malignant cells may be necessary for appropriate GPCR signaling. 
In addition to Cox-2, we demonstrated that two other LPA-target genes, IL-6 and 
uPA are also induced at least partially through activation of C/EBP-β. Thus, the effects of 
LPA on IL-6 production and uPA activation were sensitive to inhibition of EGFR. The 
comprehensive evaluation of C/EBP-β activation in regulation of gene expression by LPA 
described in the present study has further implicated this transcription factor in two 
important parts of tumor progression: inflammation and metastasis. Early immediate 
response genes such as Cox-2 require prompt transcription. The rapid induction of C/EBP-
β presence to Cox-2 promoter upon LPA stimulation (Fig. 2.12 of Chapter 2) indicate that 
C/EBP-β may play critical roles in the initiation of transcription and the recruitment of 
transcription factors and co-activators to the Cox-2 promoter [123, 143]; thus its activities 
may not be necessary for continued transcription. Unlike Cox-2, activated uPA, a member 
of a 3-component metastasis system (others are uPA receptor [uPAR] and plasminogen 
activator inhibitors 1 and 2 [PAI-1 and PAI-2]), often accumulates in late response to 
stimulation, a result of dependence on the activation of other early response genes [245-
248]. C/EBP-β appeared much later near uPA promoter upon LPA stimulation, clearly 
demonstrating that continued activation of C/EBP-β significantly contributes to both 
instantaneous and prolong or sustained induction of LPA-target genes.  
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CHAPTER 4 
DIFFERENTIAL REQUIREMENT OF RECEPTOR TYROSINE KINASE 
ACTIVITY FOR LYSOPHOSPHATIDIC ACID-INDUCED ACTIVATION OF G 
PROTEIN SIGNALING CASCADES AND TRANSCRIPTION FACTORS 
 
4.0 Abstract 
The role of the epidermal growth factor receptor (EGFR) in provoking biological 
actions of G protein-coupled receptors (GPCRs) has been one of the most controversial 
research subjects in the field of GPCR signal transduction. We and others have recently 
provided evidence for a permissive input from a receptor tyrosine kinase for activation of 
GPCR signaling [18, 232, 260]. As described in Chapter 3, LPA-induced activation of 
CEBP-β and CEBP responsive genes (Cox-2 and IL-6) requires a RTK activity. In the 
current study, we substantiated the crosstalk between the two receptor subtypes to 
determine where the RTK input is integrated with GPCR signals to stimulate transcription 
factors. In ovarian cancer cell lines, activation of AP-1 components by LPA also depended 
upon EGFR, which could be prevented by activation of another receptor tyrosine kinase c-
Met with hepatocyte growth factor (HGF), indicating that LPA-induced activation of AP-1 
requires a permissive signal from a receptor tyrosine kinase, not necessarily EGFR. In 
contrast, LPA induced activation of another prominent transcription factor NF-κB in an 
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EGFR-independent manner. These differential requirements indicate that the RTK activity 
is involved in activation of selective signaling pathways downstream of LPA receptors 
rather than activation of LPA receptors themselves. In keeping with this, EGFR was 
required for LPA-induced activation of Gi, but not Gq or G12/13 as determined by analyzing 
respective effectors of individual classes of G proteins. Further molecular and 
pharmacological experiments indicated that Gi was essential for activation of AP-1 by LPA 
while NF-κB activation lied downstream of the EGFR-independent Gq pathway. 
Consistent with essential roles for Gi and the downstream AP-1 transcription factor in 
pleiotropic biological processes, most of cellular responses to LPA such as cytokine 
production, cell proliferation, migration and invasion required intact EGFR. These results 
reveal a novel dimension of molecular mechanism for the requirement of RTK in 
transmission of GPCR signals.  
 
4.1 Introduction 
The LPA receptors couple to multiple G proteins, G12/13, Gi, Gq, and probably Gs 
[35, 39, 41, 42, 249]. These G proteins link to diverse signaling pathways including 
stimulation of phospholipase C and D [16, 49], inhibition of adenylyl cyclase [49], and 
activation of Ras and the downstream mitogen-activated protein kinases and 
phosphoinositide 3-kinase [50, 52]. Activation of these signaling cascades downstream of 
LPA receptors culminates in morphological changes and promotion of cell growth, 
survival and motility [50, 51]. Recently, we and others demonstrated that LPA induces 
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activation of transcription factors, upregulating expression of many target genes involved 
in cell proliferation, survival and migration/invasion [9, 62, 191-195].  
How LPA receptors link to transcriptional activation has become an ideal system to 
investigate the molecular mechanisms of LPA signal transduction. Many biological effects 
of GPCR have been thought to occur through transactivation of receptor tyrosine kinases, 
especially EGFR [181, 182]. In our previous studies, however, the effect of LPA on gene 
expression was much more potent than that of EGF itself. LPA indeed weakly 
transactivates EGFR as reflected by induction of low levels of phosphorylation of EGFR 
(Fig. 3.5 E of Chapter 3) which was in no means comparable to that stimulated by EGF. 
Intriguingly, the effects of LPA on gene expression were sensitive to inhibition of EGF, 
suggesting requirement of a permissive or parallel input from RTK in transducing LPA 
GPCR signals. In further support of this mode of crosstalk between GPCR and RTK, the 
dependence on EGFR could be overcome by co-stimulation of c-Met with HGF to provide 
an alternate RTK activity.  In the current study, we explored the role of EGFR in LPA-
induced activation of the transcription factors AP-1 and NF-κB. Our results indicate that 
activation of AP-1 components by LPA was highly sensitive to inhibition of EGFR while 
LPA stimulated NF-κB via an EGFR-independent manner, suggesting that EGFR activity 
is required for selective signaling cascades rather than proximal activation of LPA 
receptors. We further identified EGFR-dependent and independent G protein signaling 
cascades involved in activation of these transcription factors. Consistent with involvement 
of AP-1 in a multitude of biological processes, RTK activity is needed for LPA-induced 
cytokine production, cell proliferation, migration and invasion. 
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4.2 Materials and Methods 
 
Materials Sources of materials were as described in previous chapters. 1-Oleoly (18:1) 
LPA was obtained from Avanti Polar Lipids, Inc. (Alabaster, AL). Prior to use, these 
phospholipids were dissolved in PBS containing 0.5% fatty acid-free bovine serum 
albumin (BSA). BSA, Fugene 6 and protease inhibitor cocktail tablets were purchased 
from Roche (Indianapolis, IN). Plasmid DNA was purified using the endo-free purification 
kit from Qiagen (Valencia, CA). Luciferase assay reagents were obtained from Promega 
(Madison, WI). All oligonucleotides and primers were synthesized by Operon 
Biotechnologies, Inc (Huntsville, AL). QuikChange XL site directed mutageneis kit were 
purchased from Stratagene (La Jolla, CA). Anti-phospho p65, anti-phospho PKD  and anti-
tubulin α/β antibodies were obtained from Cell Signaling (Danvers, MA). Cell culture 
medium and lipofectamine 2000 were obtained from Invitrogen Inc. (Carlsbad, CA). 
Bovine fetal serum was from Biomeda (Foster City, CA). Enzymes were from New 
England biolab (Ipswich, MA) Hepatocyte growth factor (HGF) was obtained from R & D 
systems (Minneapolis, MN). Epidermal growth factor (EGF), AG1478, U73122, GF-
109203X and anti-β-actin monoclonal antibody were obtained from Sigma-Aldrich (St. 
Louis, MO). All other antibodies were obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA). 
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Cell Culture The sources of ovarian cancer cell lines used in the study were described 
previously [9, 192]. These cells were cultured in RPMI medium supplemented with 10% 
FBS, 100 units/ml penicillin and 100 μg/ml streptomycin. All cell lines were frozen at 
early passages and used for less than 10 weeks in continuous culture.  
 
Nuclear Extract Preparation– LPA-stimulated or control cells were washing twice with 
cold PBS, harvested by scraping with a rubber policeman and centrifuged at 1000 rpm for 
3 min. Cell pellets were resuspended in a hypotonic lysis buffer [10 mM Tris-HCl (pH 
7.4), 10 mM KCl, 3 mM MgCl2, 0.5% NP-40], incubated for 15 min on ice, and 
centrifuged at 3000 rpm. The nuclei pellet was washed once with the hypotonic lysis 
buffer, resuspended in hypertonic nuclear lysis buffer (50 mM Tris-HCl (pH 8.3), 0.4M 
NaCl, 40% glycerol, 5 mM MgCl2 and 0.1 mM EDTA) and further incubated for 10 mins 
before centrifugation at 13,000 rpm. The supernatant was collected and quick-frozen in 
liquid nitrogen before storage at -80oC. Protein concentration was determined with Pierce 
BCA kit. 
 
Western Blot Cells were lysed in SDS sample buffer or in ice-cold X-100 lysis buffer [1% 
Triton X-100, 50 mM HEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 
10% glycerol, 100 mM NaF, 10 mM Na PPi, and protease inhibitor cocktail]. Total cellular 
proteins were resolved by SDSPAGE, transferred to Immun-Blot membrane 
[poly(vinylidene difluoride)] (BIO-RAD, Hercules, CA), and immunoblotted with 
antibodies following the protocols of manufacturers. Immunocomplexes were visualized 
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with an enhanced chemiluminescence detection kit from Amersham (Piscataway, NJ) 
using the horseradish peroxidase–conjugated secondary antibodies (Cell Signaling, 
Danvers, MA). 
 
Plasmids Constructs A truncated EGFR cDNA (amino acids residues 1-677) lacking the 
cytosolic domain was cloned into pcDNA3 vector (Invitrogen, Carlsbad, CA) using 
primers: EGFR-Fwd 5’ CATAAGCTTGGAGCAGCGATGCGACCCTCC 3’ and DN-
EGFR-rev 5’CATCTCGAGGCGCTTCCGAACGATGTGG3’. The AP-1 responsive 
luciferase vector pGL2-3xAP1-Luc was made by cloning three repeats of AP-1 consensus 
binding sequence (TGATGACTCAG) in front of the minimum TK promoter and the 
luciferase gene as we described previously [9]. The NF-κB responsive luciferase vector 
pGL2-3xNF-kB-Luc was obtained from Stratagene (La Jolla, CA). The vector contains 
three repeats of the NF-κB consensus sequence (GGGGACTTTCC) cloned into the pGL2-
basic vector in front of a minimum TK promoter. The Gq dominant-negative mutant vector 
pLZRS-IRES-Gq(G208A) was kindly provided by  Dr. E. Roos [250]. 
 
Transient transfection  and luciferase assays Ovarian cancer cell lines were seeded in 6-
well plates and grown to 30-40 % confluence before transfection with the luciferase 
vectors using Fugene 6 (Roche) or TransIT-TKO (Mirus Bio Corp., Madison, WI) 
according to the instructions of the manufacturers. About 48 hours after transfection, the 
cells were starved for 24-36 hours before stimulation with LPA or vehicle for 6 hours. Cell 
extracts were prepared and assayed for luciferase activity using the luciferase assay kit 
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from Promega (Madison, WI). The luciferase activity was normalized on the basis of the 
activity of cotransfected β-galactosidase reporter driven by the cytomegalovirus promoter 
(pCMVβ-gal). Retroviral stock from EGFR-DN stable cells was a kind gift from Dr. Paul 
Dent, VCU Medical Centre. 
 
Electromobility shift assay (EMSA)- AP-1 and NF-κB consensus oligonucleotides AP-1 
sense 5’GGCGCTTGATGACTCAGCCGGAA 3’; AP-1 antisense 
5’GGTTCCGGCTGAGTCATCAAGCG 3’; NF-κB sense 
5’ATGTTGAGGGGACTTTCCCAGGCGG 3’ and NF-κB antisense 5’ 
GCCTGGGAAAGTCCCCTCAACTGG 3’ were synthesized by Operon Biotechnologies 
and annealed in 20 mM Tris (pH 7.4), 1 mM dithiothreitol, 50 mM NaCl and 10 mM 
MgCl2. Oligonucleotides were labeled at 3’ end with [α-32P]dCTP using klenow enzyme. 
For the gel shift assay, binding reaction was performed by incubating 4 μg of nuclear 
protein in gel shift buffer (10 mM HEPES (pH 7.8), 10% glycerol, 1 mM EDTA, 25 mM 
MgCl2, 50 mM KCl,  1 µg of poly(dI.dC), 3 µg BSA and protease inhibitors) in a final 
volume of 20 µL for 10 mins at 25oC. Specificity of binding with each 32P-random labeled 
probe was determined with 50-fold excess of unlabeled oligonucleotides. In supershift 
experiments, nuclear extracts were incubated for 15 min at room temperature with 1 µg of 
anti-c-Jun, anti-p65 or normal mouse IgG (Santa Cruz Biotech) prior to gel shift reaction. 
Complexes were separated by electrophoresis on 5% non-denaturing polyacrylamide gel 
  117
(PAGE). Gels were dried under vacuum and subjected to autoradiography using a 
Phosphoimager.  
 
Cell Growth Assay- The growth of Caov-3 and Skov-3 were assayed by seeding cells in 
6-well dishes at 3 to 5 x 104 cells per well in complete growth medium (RPMI 
supplemented with 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin). After 
48-72 h of culture, culture medium was replaced with serum-free medium with further 
incubation for 18 h. Cells were stimulated with or without 1 μM LPA and/or 1 μM 
AG1478 in fresh serum-free medium. Cell counts were performed on triplicate trypsinized 
cultures before and post stimulation using a cell counter (Model ZI; Coulter Electronics, 
Hialeah, FL). 
 
Migration Assay- The migration of Skov-3 cells was assayed using transwell chambers 
(pore size 8 µM) (BD Biosciences, Bedford, MA). The inserts were precoated with 
collagen. LPA (10 μM or 1 μM) or vehicle was added to the lower chamber. Serum-
starved cells (1 x 105) were loaded to the upper chamber with or without AG1478 at a final 
concentration of 1 μM. Non-migrated cells were removed from the top filter surface with a 
cotton swab. Migrated cells attached to the underside of the transwells were washed with 
PBS, stained with crystal violet and counted under a microscope. 
The invasion of SKOV-3 cells was measured using Transwells coated with growth 
factor–reduced Matrigel Basement Membrane Matrix (pore size 8 µM; BD Biosciences; 
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cat. no. 354483). The procedure for invasion was similar to that of the migration assay 
described above except that cells were allowed to invade for 20-24 h at 37°C.  
 
Scratch (Wound Closure) Assay- Confluent monolayers of Caov-3 were serum starved 
for 18 hr. Scratches were made using sterile 1 μl pipette tips. Displaced cell debris was 
washed off with serum-free media before stimulation with 5 μM LPA or BSA (vehicle) 
with or without 1 μM AG1478. Images of wounded areas were captured at 0 h and 16 h 
after addition of LPA. 
 
Rho and Ras Activation Assays- Activation of Rho and Ras were analyzed by glutathione 
S-transferase (GST) pulldown assays [251]. The cells were grown in 10-cm dishes to 
subconfluence, starved overnight, and stimulated with LPA or vehicle for the indicated 
periods of time. The cells were lysed in Magnesium-containing lysis buffer (MLB: 25 mM 
HEPES, pH 7.5, 150 mM NaCl, 1% NP40, 10% glycerol, 10 mM MgCl2, 1 mM EDTA, 1 
mM sodium orthovanadate, 10 µg/ml leupeptin, 10 µg/ml aprotinin). Clarified lysates were 
incubated for 45-60 min at 4°C with GST-Rhotekin-RBD (Rho binding domain of 
Rhotekin, residues 7-89; [252] ) or GST-Raf-RBD (Ras binding domain of Raf, residues 1-
149[253]) produced in Escherichia coli and immobilized on glutathione-coupled Sepharose 
beads. Beads were washed in MLB three times, eluted with SDS sample buffer, and 
analyzed by Western blotting using monoclonal anti-Rac antibody (BD Biosciences; Cat. 
No. 610650) or rabbit anti-Ras antibody (Cell signaling, Denvers, MA). 
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Densitometry and Statistics- Intensities of western blot bands were quantified using the 
NIH Image J software. All numerical data were presented as mean ± SD. The statistical 
significance of differences was analyzed using Student's t test where P < 0.05 was 
considered statistically significant. 
 
4.3 Results 
4.3.1 Activation AP-1 Proteins by LPA 
LPA is a master inter-cellular regulator of gene expression in mammalian cells. 
Although post-transcriptional regulation may be involved in the reinforcement of the effect 
LPA on gene expression, the initial input is driven by transcriptional activation. We have 
previously shown that the effects of LPA on gene expression are mediated by a number of 
prominent transcription factors including AP-1, NF-κB, C/EBP and Sp-1 [9, 232, 254]. 
Thus activation of transcription factors offers an ideal readout to study functions of LPA 
receptors, their downstream signaling networks and their crosstalk with RTKs. In ovarian 
and other cancer cell lines expressing LPA receptors, treatment with LPA led to induction 
of various AP-1 proteins.  
As demonstrated in Fig. 4.1 A, LPA induced c-Jun, Fos, Jun B and Fra-1 
expression in a time-dependent manner in Caov-3 cells. Induction of c-Jun and Fos 
expression occurred immediately and peaked at 1 hr after exposure to LPA. Jun B and Fra-
1 were induced at later hours and highest levels were seen at 4-6 hr of LPA treatment (Fig. 
4.1). The sequential induction of these AP-1 components could lead to sustained increases 
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in AP-1 activity. Indeed, EMSA confirmed elevation in AP-1 DNA-binding activity in 
LPA-treated cells which lasted for many hours (Fig. 4.1 B). Consistent with delayed 
induction of Jun B and Fra-1, the peak DNA-binding activity was detected after 4-6 hr of 
treatment with LPA. We further confirmed that LPA treatment resulted in transcriptional 
activation. Caov-3 cells were transfected with the AP-1 responsive luciferase reporter 
pGL2-3xAP-1-Luc. Treatment with LPA induced more than 25 fold increases in luciferase 
activity compared to untreated cells (Fig. 4.1 C). 
In these experiments, we also analyzed EGF and HGF for their ability to activate 
AP-1. The effects of LPA on AP-1 protein expression and AP-1 DNA-binding activity 
were stronger or at least comparable to those of EGF (Fig. 4.2 A and C). Since LPA 
induced only minimal activation of EGFR as reflected by weak phosphorylation at Y-1068 
(Fig. 3.5 E of Chapter 3), it is unlikely that LPA stimulated AP-1 through transactivation 
of EGFR. Compared to HGF, LPA was much more efficacious inducer of each of AP-1 
proteins and AP-1 DNA-binding activity (Fig. 4.2 B and C). For example, LPA triggered 
expression of Fos and Fra-1 while HGF failed to stimulate their expression. 
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Fig. 4.1. Activation of AP-1 expression, binding and transcriptional activity by LPA. 
A, Caov-3 cells were stimulated with 10 μM LPA for the indicated periods of time. Total cell 
lysates were blotted for c-Jun. The membrane was stripped and re-blotted for other AP-1 
components. B, Nuclear extracts obtained from Caov-3 cells stimulated with 10 μM LPA for 
the indicated periods of time were subjected to gel shift assay (EMSA) (see Materials and 
Methods). In C, Caov-3 cells were transfected with a luciferase construct of a 3-times repeat 
of AP-1 binding sites upstream of a TK promoter. Transfected cells were treated with 10 μM 
LPA  for 6 hours and analyzed for luciferase activity. 
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Fig. 4.2. Comparison of LPA to RTK agonists in activation of AP-1. 
Caov-3 cells were stimulated with 10 μM LPA, 25 ng/ml EGF or 25 ng/ml HGF for the 
indicated periods of time and analyzed by western blotting for expression of AP-1 proteins 
(A and B). Nuclear extracts obtained from Caov-3 cells stimulated with LPA, EGF or HGF 
for the indicated periods of time were subjected to EMSA using 32P-labeled AP-1 consensus 
oligonucleotides (C). 
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4.3.2 Requirement of EGFR or an alternate RTK for LPA-induced activation of AP-1 
 Having observed the dependence of LPA-induced C/EBP-β activation on RTK 
activity, we asked if this obligatory role was a general requirement for activation of 
transcription factors by LPA. Pretreatment of ovarian cancer cells with AG1478, a specific 
pharmacological inhibitor of EGFR kinase activity, abrogated LPA-induced expression of 
JunB and Fra-1 (Fig. 4.3 A). The expression of c-Jun and c-Fos was dramatically inhibited 
by the presence of AG1478. Similarly, LPA-induced AP-1 DNA binding and 
transcriptional activities were drastically suppressed by AG1478 (Fig. 4.3 B and C)   
 To determine whether EGFR is specifically needed for GPCR signaling to AP-1, 
we co-stimulated Caov-3 cells with LPA and HGF in the presence of AG1478. The 
stimulatory effects of LPA on expression of AP-1 proteins and AP-1 DNA-binding activity 
were fully recovered by co-treatment of the cells with HGF to activate the c-Met, another 
receptor tyrosine kinase (Fig. 4.3 A and B). The role of HGF was not due to activation of 
AP-1 by HGF itself as the effects of HGF on AP-1 protein expression and DNA-binding 
activity were marginal compared to those of LPA (Fig. 4.2 B and C). The restoration of 
AP-1 activity by HGF also demonstrated that AG1478 did not block LPA-induced AP-1 
activation through nonspecific or toxic effects. These results indicate that activity of a 
RTK, not necessarily EGFR, provides an activity indispensable for transmission of GPCR 
signals to AP-1 although such an activity itself is insufficient for full activation of AP-1.  
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Fig. 4.3. Requirement of RTK for LPA-induced activation of AP-1. 
Serum-starved Caov-3 cells were treated with LPA (10 μM), HGF (25 ng/ml) and/or 
AG1478 (1 μM) for the indicated time. Expression of AP-1 proteins was examined by 
Western blotting analysis (A). Nuclear extracts from LPA-treated or untreated Caov-3 cells 
were analyzed by EMSA using 32P-labeled consensus AP-1 oligonucleotides (B). In C, Caov-
3 cells transfected with a luciferase construct of a 3 copies of AP-1 consensus binding sites 
upstream of a TK promoter. Serum-starved transfected cells were then pretreated with 
AG1478, stimulated with LPA for 6 hours and examined for luciferase activity. Results are 
representative of three independent experiments. 
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Fig. 4.4. Effects of overexpression of dominant negative EGFR on LPA-induced AP-1 
protein expression. 
A, Caov-3 cells were infected for 48hours with adenoviral stock from adeno-EGFR-DN or 
control adenovirus overexpressing cells then stimulated with 10 μM LPA for the indicated 
periods of time. Total cell lysates were analyzed for expression of AP-1 proteins by Western 
blotting. Similarly, in B, AP-1 proteins expression were analyzed by western blotting after 
LPA stimulation of Caov-3 cells transfected with pcDNA3-EGFRDN or control vector. C, 
schematic representation of truncated EGFR-DN and its inhibitory function in stimulated 
condition. Only wildtype homodimers possess kinase activity, represented by phosphorylated 
tyrosine residues (red circles). 
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In further support of these results derived from pharmacological inhibition of 
EGFR, overexpression of a dominant negative, truncated form of EGFR (EGFR-DN) [255] 
in Caov-3 cells by both adenoviral transduction and direct expression plasmid suppressed 
LPA-induced expression of each of AP-1 proteins (Fig. 4.4). These pharmacological and 
molecular approaches together establish an obligatory role for EGFR or an alternate RTK 
in activation of the AP-1 transcription factor by LPA. 
 
4.3.3 EGFR-independent activation of NF-κB by LPA 
 The role of EGFR in LPA activation of CEBP-β (Chapter 3) and AP-1 raises the 
possibility that a basal RTK activity might be ubiquitously required for GPCR actions. 
This could be due to the requirement of RTK activity for activation of GPCR itself. If the 
RTK input is involved in activation of the specific intracellular G protein signaling 
processes instead of GPCR activation on the membrane, some LPA signaling pathways 
may not rely on RTK activity. To distinguish these possibilities, we examined LPA-
induced activation of another transcription factor, NF-κB, a transcription factor critical for 
activation of many LPA target genes involved in inflammation and cancer progression. As 
shown in Fig. 4.5 A-C, in Caov-3 and Skov-3 cells treated with AG1478 to block EGFR 
function, LPA induced NF-κB p65 phosphorylation, IκB phosphorylation and IκB 
degradation at levels comparable to those in control cells untreated with AG1478.  
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Fig. 4.5. EGFR-independent activation of NF-κB by LPA. 
Total cell lysates of serum-starved Caov-3 (A and C) or Skov-3 cells (B) stimulated with 10 
μM LPA and/or 1 μM AG1478 for the indicated periods of time were analyzed by Western 
blotting for phosphorylated NF-κB p65. The membrane was reprobed with anti-phospho-
IκBα (B) or anti-IκBα (C).  IKKα/β, β-actin or Tubulin were used to show equal loading. c-
Jun or c-Fos expression was used to confirm efficacy of batch of AG1478 used in 
experiment.  
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Fig. 4.5 (cont’d). EGFR-independent activation of NF-kB by LPA 
D, Nuclear extracts obtained from Caov-3 cells stimulated with 10 μM LPA or 1 μM 
AG1478 for the indicated periods of time were subjected to EMSA. Supershift experiments 
were performed on 4-h LPA-treated nuclear extracts using 2 and 5 μg anti-p65 mouse 
monoclonal antibody. For dephosphorylation of nuclear extracts, 1 unit of potato alkaline 
phosphatase (PAP) was added for 15 min prior to binding reaction In E, Caov-3 cells were 
transfected with a luciferase construct of a 3-times repeat of NF-κB binding sites upstream of 
a TK promoter. Transfected cells were treated with 10 μM LPA for 6 hours and analyzed for 
luciferase activity. F, Caov-3 cells were infected for 48 hours with adenoviral stock from 
adeno-EGFR-DN or control adenovirus overexpressing cells at 30 MOI, then stimulated with 
10 μM LPA for the indicated periods of time (upper). In similar experiments, Caov-3 cells 
were transfected with pcDNA3-EGFR-DN or control vector (lower) and stimulated with 
LPA for 2 hrs. Total cell lysates were analyzed for phosphorylated p65 by Western blotting.  
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Similarly, LPA-stimulated NF-κB DNA-binding activity was not compromised by 
AG1478 as measured by EMSA (Fig. 4.5 D); nor was LPA-driven NF-κB transcriptional 
activity significantly ablated by incubation of cells with AG1478 as analyzed by the NF-
κB responsive luciferase reporter assay (Fig. 4.5 E). Further, overexpression of dominant 
negative EGFR (EGFR-DN) did not interfere with LPA-induced p65 phosphorylation (Fig. 
4.5 F) despite strong inhibitory effect of EGFR-DN on AP-1 protein expression (Fig. 4.4). 
Therefore, in sharp contrast to AP-1 activation, LPA-elicited NF-κB activity occurs via an 
EGFR-independent route. The results also indicate that the crosstalk with RTK is required 
only for a selective subset of biochemical events but not overall activities of LPA 
receptors.   
 
4.3.4 G protein cascades mediating LPA-induced AP-1 and NF-κB activation 
 To identify the mechanism for the differential requirements of RTK in transmitting 
GPCR signals to AP-1 and NF-κB, we examined G protein signaling cascades responsible 
for activating AP-1 and NF-κB. The classical Edg LPA receptors expressed in cancer cell 
lines couple to Gi, Gq and G12/13 [36-42]. Inhibition of Gi with pertussis toxin (PTX) 
strongly decreased LPA-induced AP-1 proteins c-Jun and c-Fos as shown in Fig. 4.6 A, 
indicating that Gi signaling links to AP-1 activation by LPA. However, Gi was disposable 
for NF-κB activation as PTX did not interfere with NF-κB p65 phosphorylation induced 
by LPA.  
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Fig. 4.6. G proteins cascades mediating LPA-induced AP-1 and NF-κB activation 
Caov-3 cells were stimulated with 10 μM LPA and/or, in A, 25 ng/ml PTX (Gi inhibitor), 5 
μM U73122 (PLCγ inhibitor) or 10 μM Y27632 (ROCK inhibitor) (C) for the indicated 
periods of time. Total cell lysates were analyzed by Western blotting for phospho-p65, c-Jun 
or c-Fos. In B, Caov-3 cells were transfected with expression plasmid, pcDNA3-GqG208A, 
dominant negative of Gq. Transfected cells were treated with 10 μM LPA  for 6 hours and 
analyzed by Western blotting. 
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To assess the contributions of Gq signaling cascade to AP-1 and NF-κB activation, 
we took advantage of a dominant negative form of Gq (G208A) that has been shown to 
specifically block Gq–mediated pathways in different cell systems [250, 256, 257]. The 
GqG208A was transfected into Caov-3 cells using Amaxa nuocleofector Kit T that yield 
high transfection efficiency in ovarian cancer cell lines as we described previously 
(Chapter 2, Materials and Methods). Expression of the GqG208A mutant almost 
completely prevented LPA-induced p65 phosphorylation but not c-Jun expression (Fig. 4.6 
B). Induction of Fos by LPA was decreased by overeexpression of GqG208A. Due to the 
lack of commercially available Gq pharmacological inhibitors, we made use of U73122, an 
antagonist of PLC that lies downstream of Gq [16, 49]. U73122 inhibited LPA-induced 
NF-κB p65 phosphorylation and c-Fos induction (Fig. 4.6 C). Only slight reduction in 
LPA-induced c-Jun expression was observed in U73122-treated cells. These data establish 
that the Gq-mediated signaling is critical for NF-κB activation in response to LPA. 
Activation of Gq may also contribute to LPA induction of certain AP-1 proteins such as c-
Fos.   
We also examined the role of G12/13 in LPA-mediated activation of AP-1 and NF-
κB through inhibition of the G12/13 effector ROCK. ROCK has been reported to participate 
in LPA-induced c-Jun expression in NIH 3T3 cells [258]. We examined the effects of a 
highly selective ROCK inhibitor Y-27632 on LPA-induced AP-1 and NF-κB activation. 
The compound did not affect LPA-induced p65 phosphorylation but compromised c-Jun 
and c-Fos induction (Fig. 4.6 C). Based on these results, each of G protein modules (Gi, 
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Gq, and G12/13) seems to contribute to AP-1 activity while only the Gq pathway couples to 
NF-κB activation in LPA-stimulated cells.    
 
4.3.5 Differential requirement of EGFR for activation of G signaling cascades 
 We next explored whether EGFR is differentially required for activation of 
intracellular G protein signaling modules. Since it is practically difficult to analyze 
activation of G proteins, we examined the downstream effectors of each class of G proteins 
coupled to LPA receptors. Ras activation is a well-defined Gi-dependent signal, Rho lies 
downstream of G12/13 and activation of Gq could be monitored by analyzing the PKC-PKD 
pathway. As demonstrated in Fig. 4.7 A, LPA-induced Ras activation was completely 
blocked by AG1478 as measured by GST pulldown assay for the GTP-bound Ras (GTP-
Ras). In agreement with EGFR-dependent activation of Ras by LPA, Erk activation was 
also highly sensitive to AG1478 (Fig. 4.7 B), suggesting that LPA-induced activation of Gi 
relies on a permissive signal from EGFR. However, the GST pulldown analysis of Rho 
activation demonstrated that EGFR was not involved in activation of G12/13 as the 
downstream Rho was fully activated by LPA in the presence of AG1478 (Fig. 4.7 C). PKD 
is a well characterized substrate of various isoforms of PKC [259]. LPA stimulated a rapid 
and sustained PKD phosphorylation at Serine 916 (Fig. 4.8A). Blockade of PKC with GF-
109203X specific inhibitor of classical PKCs, or inhibition of PLCγ with U73122 (Fig. 4.8 
C) prevented LPA-induced phosphorylation of PKD, confirming that the PLC-PKC 
cascade lies upstream of PKD.  
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Fig. 4.7 Differential effects of EGFR inhibition on Ras and Rho activation by LPA 
Serum-starved Caov-3 cells were stimulated with 10 μM LPA and/or 1 μM AG1478 for the 
indicated periods of time. Ras (A) or Rho (C) in cell lysates was concentrated by glutathione 
S-transferase (GST) pulldown assays (see Materials and Methods). Samples from pull-down 
assay and inputs were analyzed by Western blotting. In B, Caov-3 cells treated with LPA 
and/or indicated dose of AG1478 for 4 hours were analyzed for phosphorylated MAPK (anti-
phospho Erk) by Western blotting. 
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Fig. 4.8. EGFR-independent activation of Gq signaling pathway by LPA. 
Serum-starved Caov-3 cells were stimulated with 10 μM LPA and/or 0.2 μM GF109203X, 
10 μM U73122 or 1 μM AG1478 for the indicated periods of time. Total cell lysate were 
analyzed by Western blotting with anti-phosphoPKD (Ser 916) (A-C) In D, Caov-3 cells 
were transfected with pcDNA3-EGFRDN or control vector, stimulated with 10 μM LPA for 
2hrs and subjected to Western blotting analysis. β-actin was used as control for equal 
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However, inhibition of EGFR function with AG1478 or EGFR-DN did not affect 
PKD phosphorylation induced by LPA (Fig. 4.8 C and D). Therefore, activation of the Gq-
PLC-PKC-PKD pathway does not require EGFR activity. These results reveal EGFR-
dependent Gi and EGFR-independent Gq and G12/13 signaling cascades downstream of LPA 
receptors. Since these G protein pathways are linked to activation of specific transcription 
factors as specified above, these results provide a molecular basis for the differential 
requirements of EGFR in LPA-stimulated activation of the AP-1 and NF-κB transcription 
factors.  
 
4.3.6 Essential roles of EGFR in multiple biological responses to LPA 
 If Gi and the downstream AP-1 depend on EGFR for activation, we expected that 
many cellular processes mediated by Gi or AP-1 are sensitive to EGFR inhibition. To 
further test this speculation, we first examined the effect of EGFR inhibition on LPA-
induced IL-8 production, a functional outcome of synergistic actions of NF-κB and AP-1 
as we described previously [9]. As demonstrated in Fig. 4.9 A, the prominent effect of 
LPA on IL-8 production was suppressed by inhibition of EGFR with AG1478, consistent 
with the necessity of EGFR for LPA-induced AP-1 activation. Further analysis of other 
cellular responses to LPA demonstrated that inhibition of EGFR suppressed LPA-afforded 
cell growth (Fig. 4.9 B). LPA-mediated migration, invasion and wound closure in ovarian 
cancer cell lines were also attenuated in the presence of AG1478 (Fig. 4.9 C-E), in support 
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of essential roles of EGFR-dependent Gi and its downstream signaling pathways in 
promotion of a broad range of cellular responses to LPA [18, 260].  
 
Fig. 4. 9. Role of EGFR in LPA-mediated biological responses. 
A, Cultured supernatants of serum-starved Caov-3 cells pretreated with or without 1 μM 
AG1478 and stimulated with 10 μM LPA for 18hrs were assayed for IL-6 concentrations by 
ELISA. In B, triplicate samples of Caov-3 or Skov-3 cells were serum starved for 12hrs, 
stimulated with 5 μM LPA and/or 1 μM AG1478 for the indicated period of time. Cells were 
trypsinized and quantified in  a cell counter.  
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Fig. 4.9 (cont’d). Role of EGFR in LPA-mediated biological responses 
Caov-3 cells were serum starved and seeded in collagen-coated (C) or growth factor–reduced 
matrigel basement membrane matrix (D) transwell chambers (see Materials and Methods). 
Migration or invasion of cells were assessed by stimulating cells with 10 μM LPA and/or 1 
μM AG1478 for 6 and 24 hours respectively. Number of migrated or invaded cells was 
counted in 8 randomly selected fields across membrane. E, serum-starved confluent 
Caov-3 cells were scratched with sterile pipette and stimulated with LPA and/or AG1478. 
Images were captured immediately after scratch and 16 hours post-stimulation. Data shown 
are representative of three independent experiments. 
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4.4 Discussion 
We have previously shown that LPA induces expression of multiple cancer-
associated genes via activation of transcription factors [9, 232, 254]. In Chapter 2 and 3, 
we used LPA-induced Cox-2 expression as a model system to identify transcription factors 
and signaling networks involved in activation of Cox-2 expression by LPA. Through these 
studies, we demonstrated that CEBP-β is a key transcription factor responsible for 
initiating transcription of Cox-2. The activation of CEBP-β by LPA results from 
integration of signals from LPA receptor(s) and a permissive activity from RTK. To 
substantiate this crosstalk between GPCR and EGFR in transmission of GPCR signals, we 
have devoted the study in this Chapter to determining whether the EGFR signal is 
generally required for activation of other transcription factors by LPA. The results 
presented here indicate that LPA-induced activation of AP-1 relies on such an activity 
from EGFR in analogy to LPA-mediated C/EBP-β activation while LPA stimulates NF-κB 
in an EGFR-independent manner. The differential requirements of EGFR for AP-1 and 
NF-κB activation suggest that the EGFR signal is involved in activation of specific 
intracellular signaling cascades downstream of LPA receptors rather than proximal 
activation of LPA receptors on the membrane. Furthermore, we identified the intracellular 
G signaling cascades that interact with EGFR. Our results revealed that the Gi-mediated 
pathway relies on an EGFR input for activation while Gq and G12/13 signals are refractory 
to inhibition of EGFR. AP-1 activation by LPA heavily depends on the Gi pathway and 
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accordingly is EGFR dependent. On the other hand, activation of NF-κB by LPA is 
mediated through an EGFR-independent Gq signaling process. 
The crosstalk between RTK and GPCR in cellular functions has been a subject of 
extensive research in the area of signal transduction [18, 260]. Both “transactivation” and 
“permissive signal” models have been proposed to explain the functional dependence of 
GPCR signals on RTK [260]. In our studies using ovarian cancer cell lines, we did not 
observe strong transactivation of EGFR by LPA as reflected by only weak induction of 
EGFR phosphorylation (Fig. 3.5 E of Chapter 3). In addition, the effects of LPA on 
activation of transcription factors and the downstream gene expression were generally 
speaking more profound than EGF itself. Therefore, it is hard to imagine that LPA induces 
these biochemical and biological events through transactivation of EGFR. In contrast, our 
results are in concert with a permissive role of EGFR or an alternate RTK in activation of 
GPCR signaling. Elucidation of EGFR-dependent and EGFR-independent G protein 
signaling cascades and their downstream biochemical events allow us to conclude that only 
selective GPCR signaling pathways are regulated by EGFR.  
It remains to be determined how EGFR is integrated with GPCR signaling to 
activate Gi and events downstream of Gi. As shown in this Chapter, again, the role of 
EGFR could be substituted for by activation of another RTK such as c-Met. The 
observation indicates that a RTK activity, not necessarily EGFR, is involved in linking 
GPCR to Gi activation.  It has been well documented that EGFR is overexpressed or 
activated through mutation in many types of human cancers including ovarian cancer [244, 
260]. It is conceivable that the elevated EGFR activity in cancer cells likely functions as a 
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default RTK to interact with GPCR signals. The basal, unstimulated activities of other 
RTKs may not be sufficiently high to provide such a permissive signal. However, when 
activated by their specific ligands, these other RTKs such as c-Met may function as 
alternate RTKs to interact with GPCR signals. Targeting EGFR has been an attractive 
approach to cancer intervention. Based on our results presented in this chapter, EGFR is 
essential for many biological processes evoked by GPCRs including cytokine production, 
cell proliferation, and cell migration and invasion. Many GPCR agonists are important 
mediators of these biological processes in cancer cells. Thus, inhibition of EGFR may 
yield therapeutic benefits from interference with GPCR signaling in addition to 
disconnection of EGFR from its own direct downstream effectors. 
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CHAPTER 5 
GENERAL DISCUSSION 
  
LPA is present in the blood at sub-micromolar concentrations [19, 20]. It is one of 
growth factors found in ascitic fluids of ovarian cancer patients [4, 6, 261]. Elevated 
plasma levels of LPA are found at both early and advanced stages of ovarian cancer, 
offering LPA as a potential biomarker for early detection of the malignancy [4, 5, 262]. 
LPA receptors are also overexpressed in primary ovarian cancer and ovarian cancer cell 
lines [35, 59, 263, 264]. LPA stimulates proliferation, survival and motility of ovarian and 
other types of cancer cells [3, 7, 29]. LPA presence in tumor microenvironment enhances 
aggressiveness of cancer cells at least partially through modulating expression of diverse 
target genes ranging from inflammatory cytokines to proteases.  
Dysregulated gene expression is a hallmark of tumorigenesis. The overall aim of 
my project was to delineate the mechanistic details of LPA-induced gene expression in 
ovarian cancer cells wherein LPA has been implicated as an activating factor. 
Identification of major components of LPA signal transduction leading to gene expression 
may offer novel therapeutic targets for treatment of ovarian cancer and other human 
malignancies. The current work demonstrated that (i) LPA upregulates gene expression at 
both transcriptional and post-transcriptional levels; (ii) LPA triggers transcriptional 
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activation through activating major transcription factors such as AP-1, NF-κB and C/EBP; 
(iii) LPA activates transcription factors via RTK-dependent and independent pathways.  
As described in Chapter 2, we analyzed the molecular mechanisms by which LPA 
stimulated expression of the Cox-2 gene in ovarian cancer cells. Cox-2 is an important 
inducible enzyme in the formation of prostanoids including prostaglandins, prostacyclins 
and thromboxanes. Targeting Cox-2 with non-steroidal anti-inflammatory drugs (NSAIDs) 
provides relief from symptoms of pain and inflammation [207]. Since selective inhibition 
of Cox-2 also reduces the risk of colon cancer [265, 266], it is generally believed that Cox-
2 contributes to the pathogenesis of human cancer including ovarian cancer [267]. 
Therefore, it was of interest to study how the Cox-2 gene is regulated in cancer cells.   
Compared to many peptide growth factors, LPA was more potent inducer of Cox-2 
expression in ovarian cancer cell lines, an effect mediated by multiple LPA receptors 
including LPA1, LPA2 and LPA5. In addition to the striking potency, another feature we 
observed was the prolonged duration of Cox-2 induction by LPA. LPA-induced Cox-2 
expression remained highly elevated 16 hours after exposure to LPA, in sharp contrast to 
the transient induction of Cox-2, as an early response gene, by other agonists. Analysis of 
Cox-2 mRNA stability revealed that it was significantly enhanced in LPA-treated cells. We 
further identified HuR as an mRNA stability factor that bound to Cox-2 transcripts at 3’-
UTR and protected them from degradation. Knockdown of HuR expression with siRNA 
attenuated the prolonged stimulation of Cox-2 by LPA, confirming an active role of HuR 
in sustaining Cox-2 expression in LPA-treated cells. At present, it is not known whether 
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LPA activates HuR through biochemical modifications or whether the association of HuR 
and Cox-2 mRNA is solely dependent on increased transcript levels of the latter.  
An important observation made in Chapter 2 was the crucial role of C/EBP-β in 
transcriptional initiation of Cox-2 gene expression in response to LPA. In contrast to other 
studies implication of AP-1 and/or NF-κB in inducible Cox-2 expression, we observed 
minimal contributions of these factors to LPA-induced Cox-2 expression. In fact, 
expression of a dominant negative form of c-Jun (Tam67) modestly potentiated LPA-
induced Cox-2 expression. The finding of the essential and unique role of C/EBP-β in 
driving Cox-2 expression by LPA was somewhat surprising to us as C/EBP-β had not been 
implicated in any biological effects of LPA. However, our results from multiple 
approaches including promoter analysis, ChIP assay, and expression of dominant negative 
of C/EBP-β, LIP all pointed to critical involvement of C/EBP-β in activation of the Cox-2 
gene promoter in LPA-stimulated cells. 
In Chapter 3, we extended to investigate the molecular mechanism for activation of 
C/EBP-β by LPA and the general role of this transcription factor in LPA-mediated gene 
expression. We focused on the C/EBP-β isoform because it was abundantly expressed in 
ovarian cancer and correlated with aggressiveness of the disease [135]. We showed that 
LPA induced a rapid phosphorylation of C/EBP-β and its DNA-binding and transcriptional 
activities. The C/EBP-β phosphorylation is one of the major biochemical events associated 
with its activation [121, 125, 126]. Since the C/EBP-β phosphorylation correlated well 
with DNA-binding and transcriptional activities in LPA treated cells, it is likely that LPA-
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induced phosphorylation represent a key step leading to functional activation of the 
transcription factor although the impacts of LPA on other biochemical changes associated 
with C/EBP-β activation, such as ubiquitination, sumoylation and acetylation, are yet to be 
assessed and therefore should be a focus of future studies. 
Some mammalian cells carry C/EBP-β in the cytosol and nucleus and activation of 
C/EBP-β commensurate with an increased nuclear translocation of the protein [142, 268]. 
In ovarian cancer cells, however, C/EBP-β was exclusively seen in the nuclei and LPA 
treatment did not change such a distribution pattern. Thus, nuclear translocation is not a 
mechanism to activate transcriptional capacity of C/EBP-β. In addition, the kinase that 
activates nuclear C/EBP-β upon LPA stimulation has not been identified. Considering the 
role of C/EBP-β in the induction of Cox-2 expression by LPA, it is unlikely that nuclear 
C/EBP-β kinase would be of MAPK lineage given that inhibition of MAPK cascade did 
not block LPA-induced Cox-2 expression. The detail of that unique LPA GPCR-activated 
pathway that bypasses MAPK signaling components may be critical not only for the 
identification of nuclear C/EBP-β kinase but perhaps for the discovery of more upstream 
targets of Cox-2 activity. Moreover, the export of C/EBP-β out of the nucleus by nuclear 
exportins has been shown to result in repression of certain genes. Thus, temporal 
manipulation of C/EBP-β levels via nuclear export may be an attractive therapeutic option. 
 Overexpression of LAP was not sufficient to increase C/EBP-β transcriptional 
activity strongly suggesting that LPA-mediated CEBP-β activation is due to biochemical 
modification of C/EBP-β rather than in an increase in overall CEBP-β protein levels. In 
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extended stimulation conditions, activation and expression of C/EBP-β-target genes may 
continue to benefit from continual presence of LPA, such as is found in the ascites of 
ovarian cancer patients. By extending our study to other LPA-target genes, we 
demonstrated that, in addition to Cox-2, C/EBP-β was also involved in LPA induction of 
inflammatory cytokine IL-6 and metastatic factor uPA, underscoring a general role of 
CEBP-β in modulation of multiple LPA target genes.   
A highlight of the work described in Chapter 3 is the finding of the dependence of 
C/EBP-β activation on crosstalk between LPA GPCRs and EGFR. The effects of LPA on 
CEBP-β phosphorylation, DNA-binding and transcriptional activities and the ultimate 
induction of Cox-2 were all sensitivity to inhibition of EGFR kinase activity with AG1478. 
LPA-induced IL-6 and uPA gene expression was also impaired by inhibition of EGFR, 
further substantiating C/EBP-β as rate-limiting factor in LPA-induced Cox-2, IL-6 and 
uPA expression. It is interesting to note that the dependence on EGFR could be overcome 
by activation of another RTK c-Met. In recovery experiments, costimulation with HGF 
efficiently revoked the suppression imposed by EGFR inhibition. This observation 
suggests that a receptor tyrosine kinase activity, not specifically EGFR, is required for 
LPA-induced activation of C/EBP-β and expression of the downstream targets. The reason 
that EGFR plays such a default role is most likely due to the fact that the basal EGFR 
activity is more prominent than other RTKs, particularly in malignant cells where EGFR is 
commonly overexpressed and activated through mutations [244, 260]. Another interesting 
question is whether the basal, unstimulated activity of EGFR in ovarian cancer cells is 
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sufficient to provide such as permissive signal for GPCR activation of CEBP-β. 
Alternatively, EGFR could be “transactivated” during LPA stimulation. However, we 
observed only weak activation of EGFR by LPA compared to the marked effect of EGF 
itself in ovarian cancer cell lines. It is difficult to fit our observations into the 
“transactivation” model given the fact that full activation of EGFR by EGF only triggers 
weak activation of C/EBP-β and Cox-2 expression. Therefore our results are more 
compatible with the hypothesis that a basal EGFR activity is necessary for transmission of 
GPCR signaling to C/EBP-β activation.   
To further characterize the crosstalk between GPCR and RTK in activation of 
transcription factors, we next asked whether the RTK signal is a general requirement for 
activation of other transcription factors by LPA. As described in Chapter 4, we examined 
LPA-induced activation of AP-1 and NF-κB in ovarian cancer cell lines. Interestingly, AP-
1 activation in response to LPA indeed relied on EGFR activity analogous to LPA-induced 
C/EBP-β activation. However, LPA stimulated NF-κB activation independently of EGFR 
activity. Hence, the intact EGFR is differentially required for activation of these prominent 
transcription factors. NF-κB activation by LPA offers an excellent readout of EGFR-
independent signals downstream of LPA receptors. It however leaves with us a quest to 
identify more EGFR-independent transcription factors and genes. Such molecules may be 
involved in unknown mechanisms through which ovarian tumor cells exhibit resistance to 
EGFR therapy [269]. A microarray analysis of LPA-induced transcriptome in cells 
pretreated with EGFR inhibitors would be an excellent methodology through which such 
informative profile may be obtained. 
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Molecular and pharmacological approaches demonstrated that activation of AP-1 
and NF-κB were mediated by different G protein signaling cascades downstream of LPA 
receptors. The EGFR-independent Gq pathway was a mediator of NF-κB while the EGFR-
dependent Gi signaling cascade was the predominant and most critical player in LPA-
induced activation of AP-1. These results presented in Chapter 4 provide in-depth insights 
Fig. 5.1. Hypothetical model of activation of G proteins and transcription factors by 
LPA. 
Obligatory inputs from basal EGFR activity may feed into signals downstream of LPA 
receptors at diverse points, particular before and/or after activation of Gi. Activation of AP-1 
by LPA is mediated by activation of multiple G proteins. However, NF-κB is activated 
downstream of Gq signaling cascade.  
AP-1
LPA#EGFR
P
P
P
P
Gq
G12/13
Gi
NF-κB
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into the role of EGFR in activation of intracellular G proteins and their downstream 
molecules.  
The hypothetical model depicted by Fig. 5.1 simplifies the current status of this 
project as well as future prospects. It will be of particular interest to elucidate how EGFR 
activity is involved in activation of Gi in cooperation with GPCR. It is also possible that 
EGFR is required for activation of a Gi effector that is located downstream of Gi but 
upstream of Ras. Another direction is to find the link between Gi and C/EBP-β. Based 
upon the observation that both Gi and C/EBP-β activation rely on EGFR activity, we 
predict that phosphorylation of C/EBP-β lies downstream of Gi. We have already assessed 
a number of Gi-mediated signals including the MAPK pathways. We have unfortunately 
not confirmed the connection yet. 
The Gi signaling is essential for many biological responses to LPA and other GPCR 
ligands. We observed significant but incomplete inhibition of LPA-induced cell 
proliferation, migration and invasion by EGFR inhibitors. These results suggest that 
EGFR-independent, Gq or G12/13-medaited signals could be operational partially mediating 
these responses. Thus, simultaneous targeting EGFR and LPA receptors seems to be an 
appealing approach to inhibit proliferation, invasion and metastasis of ovarian cancer cells. 
This could be evaluated both in vitro and in vivo.  
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